Renowned Expert Steve Gormley Joins the Board of International Cannabrands Ltd

Calgary, Alberta (FSCwire) – International Cannabrands Inc. (CSE:JUJU.A; FSE:31G; US OTC:GEATF) (the “Company”) is pleased to announce that Steve Gormley has joined the Board of Directors for the Company.

Steve is a renowned expert in the legal marijuana sector and whose analysis is featured prominently in outlets like Forbes, Wall Street Journal, CBS News, US News and World Report, Chicago Tribune, and Marketwatch. From 2012 to 2016, Steve served as Chief Business Development Officer and member of the Board of Directors for OSL Holdings, a publicly traded management services in the cannabis industry. OSL Holdings owned and operated a hydroponics retail gardening supply enterprise. Steve also founded and served as CEO at Seventh Point, LLC., a private equity firm that focused on acquiring legal and compliant dispensaries in Los Angeles.  Steve is presently President of Alta Via, a management services company working to secure a Measure M cultivation and manufacturing licenses in Los Angeles.  Steve also currently serves at Chief Operating Officer for Silverback Holdings, a management services company applying for cultivation, dispensary and manufacturing licenses in Michigan.  Steve has been in the legal marijuana business for nearly seven years working in both public and private ventures in the space.

Steve Gormley has nearly twenty years’ experience developing, branding, marketing, launching, managing and operating businesses in the US and international markets. He has lived and worked in Asia, Europe, South America and Australia. Steve got his start in media in television production in the early 90s. After developing content and producing for MTV, Paramount Pictures, Tribune and others, Steve leveraged his expertise in content into the on-line sector for a new media private equity fund in the late 90’s and early part of the new century. Steve helped develop, launch, manage and sell a number of new media properties and eventually founded a branded entertainment company in China. Steve has also served as managing director for a California based media private equity fund. He deployed C-Level Management Services specializing in startups and turn-arounds.

Travis Belcher, President of the Company said: “We have tremendous respect for Steve for his accomplishments in the industry, exceptional business acumen and personal integrity. We are honored to have him join us and think he will be a great fit for JuJu Royal and our other initiatives.”

Steve Gormley commented: “JUJU Royal is on track to become one of the most formidable brands in the cannabis industry.  I am excited to be part of this exceptional enterprise and look forward to working with the team at JUJU.”

About International Cannabrands Ltd.

International Cannabrands acquired the exclusive rights to Julian Marley’s JuJu Royal™ brand to educate people about the natural connection between Julian Marley, Rastafarian culture, reggae music, and marijuana. International Cannabrands generates revenue from licensing brands to growers, edible manufacturers, oil extractors, producers of ancillary products and apparel in the United States where cannabis has been legalized at the state level, as well as products containing CBD in the US and internationally. Select JuJu Royal products are available in California, Washington, Colorado and Puerto Rico with CBD-only products available in the U.K., the birthplace of Julian Marley. The Company is looking to expand JuJu Royal into Nevada in the near future. The company was founded in 2014 and is based out of Denver, Colorado. The Company believes as the market becomes saturated with products varying in potency and quality, that the branded products will rise to the top and the Company intends to exploit all opportunities available to realize the full value of the Julian Marley brand and to attract other brands.

About JuJu Royal

Julian Marley conveys his message of legalization, freedom, and love through the JuJu Royal brand, a line of naturally produced medicinal herbs using the best solventless technology. One percent of proceeds are distributed for the benefit of veterans using cannabis through the Weed for Warriors Project. More information about the brand and various products can be obtained at www.jujuroyal.net. International Cannabrands Ltd is continuing to work with Julian Marley to identify and develop future strains of marijuana that meet Julian’s exacting standards. The Company is continuing to conduct research and development with certain origin genetics to produce additional signature Julian Marley strains for the JuJu Royal Premium Marijuana collection. The intent is to make these strains available to dispensaries and caregivers on a worldwide basis where it is legal.

 

International Cannabrands Contact:

Jeffrey Britz                                                                CFN Media Contact:

Chairman & CEO                                                        Frank Lane (206) 369-7050

1045 Lincoln Street, #106                                           flane@cannabisfn.com

Denver, Colorado 80203

201-394-7882 or jeffrey@jujuroyal.net

Media Inquiries:  media@jujuroyal.net

 

NEITHER THE CANADIAN SECURITIES EXCHANGE NOR THEIR REGULATION SERVICES PROVIDER HAVE REVIEWED OR ACCEPT RESPONSIBILITY FOR THE ADEQUACY OR ACCURACY OF THIS RELEASE.

Source: International Cannabrands Inc. (CSE:JUJU.A, OTC Bulletin Board:GEATF)

To follow International Cannabrands Inc. on your favorite social media platform or financial websites, please click on the icons below.

  

The post Renowned Expert Steve Gormley Joins the Board of International Cannabrands Ltd appeared first on CannabisFN.

InMed Rings the Opening Bell at the Toronto Stock Exchange

VANCOUVER , April 17, 2018 /CNW/ – InMed Pharmaceuticals Inc. (“InMed” or the “Company”) (TSX:IN; OTCQB:IMLFF), a fully integrated, cannabinoid-based biopharmaceutical company that leverages its proprietary bioinformatics and biosynthesis platform technologies to develop novel therapeutics for the treatment of diseases with high unmet medical needs, announced that the Company will ring the opening bell at the Toronto Stock Exchange (“TSX”) today in honor of its migration to the exchange on March 26, 2018 .

InMed Pharmaceuticals Inc. (CNW Group/InMed Pharmaceuticals Inc.)

Eric A. Adams , InMed’s President and Chief Executive Officer, stated, “As the Company continues to build recognition in the capital markets and grow its exposure to a broader and more diverse investor audience, we’re proud to celebrate our successful migration to the TSX today.”  Mr. Adams continued, “I would also like to take this opportunity to acknowledge and thank our employees, investors and partners who have supported InMed in our many accomplishments to date.  The integration of our proprietary drug-disease targeting platform and novel biosynthesis process, which we anticipate will deliver therapeutic compounds designed to treat multiple diseases with high unmet medical needs, is genuinely disruptive in the emerging cannabinoid space” concluded Mr. Adams.

About InMed:
InMed is a preclinical stage biopharmaceutical company specializing in the research and development of novel, cannabinoid-based prescription drug therapies utilizing novel drug delivery systems. InMed conducts research, discovery, preclinical, regulatory, manufacturing and commercial development activities for its product candidates. InMed’s proprietary bioinformatics platform, its biosynthesis manufacturing process and its drug development programs are the fundamental value drivers of the Company. For more information, visit www.inmedpharma.com.

Cautionary Note Regarding Forward-Looking Information:
This news release contains “forward-looking information” and “forward-looking statements” (collectively, “forward-looking information”) within the meaning of applicable securities laws. Forward-looking information is based on management’s current expectations and beliefs and is subject to a number of risks and uncertainties that could cause actual results to differ materially from those described in the forward-looking statements. Forward-looking information in this news release includes statements about: delivering therapeutic compounds designed to treat multiple diseases with high unmet medical needs; Mr. Adams being featured in a television interview with Business News Network; and the expected fundamental value drivers of the Company.

With respect to the forward-looking information contained in this news release, InMed has made numerous assumptions regarding, among other things: continued and timely positive preclinical and clinical efficacy data; the speed of regulatory approvals; demand for InMed’s products; and continued economic and market stability. While InMed considers these assumptions to be reasonable, these assumptions are inherently subject to significant business, economic, competitive, market and social uncertainties and contingencies.

Additionally, there are known and unknown risk factors which could cause InMed’s actual results, performance or achievements to be materially different from any future results, performance or achievements expressed or implied by the forward-looking information contained herein. Known risk factors include, economic or market conditions may worsen; and InMed’s proprietary bioinformatics platform, biosynthesis manufacturing process and drug development programs may not deliver therapeutic compounds designed to treat multiple diseases with high unmet medical needs nor become the fundamental value drivers of the Company . A more complete discussion of the risks and uncertainties facing InMed is disclosed in InMed’s most recent Annual Information Form and other continuous disclosure filed with Canadian securities regulatory authorities on SEDAR at www.sedar.com.

All forward-looking information herein is qualified in its entirety by this cautionary statement, and InMed disclaims any obligation to revise or update any such forward-looking information or to publicly announce the result of any revisions to any of the forward-looking information contained herein to reflect future results, events or developments, except as required by law.

NEITHER THE TORONTO STOCK EXCHANGE NOR ITS REGULATIONS SERVICES PROVIDER HAVE REVIEWED OR ACCEPT RESPONSIBILITY FOR THE ADEQUACY OR ACCURACY OF THIS RELEASE.

Cision

View original content with multimedia:http://www.prnewswire.com/news-releases/inmed-rings-the-opening-bell-at-the-toronto-stock-exchange-300630471.html

SOURCE InMed Pharmaceuticals Inc.

The post InMed Rings the Opening Bell at the Toronto Stock Exchange appeared first on CannabisFN.

Lexaria Achieves Significant Breakthrough in Alternative Nicotine Delivery Technology

KELOWNA, BC / ACCESSWIRE / April 17, 2018 / Lexaria Bioscience Corp. (LXRP) (LXX.CN) (the “Company” or “Lexaria”), a drug delivery platform innovator, is pleased to announce positive topline results upon completion of its first ingestible nicotine in vivo(animal) absorption study. Lexaria is pursuing the use of its patented DehydraTECHTMtechnology as a possible new nicotine delivery method, an edible dose absorbed through the gastrointestinal tract, with potential both as a nicotine replacement therapy as well as an alternative product format for regular tobacco users.

DehydraTECHTM delivered the following major nicotine absorption performance improvements:

  • 1,160% faster delivery of equivalent peak quantities of nicotine to the bloodstream than achieved with controls (within 15 min vs. 2.9 hours);
  • 148% gain in the quantity of peak nicotine delivery to the bloodstream relative to controls;
  • 560% higher brain levels of nicotine where nicotine effects are focused, compared to controls;
  • Lower urine levels of nicotine excreted than controls, for enhanced nicotine activity and bioavailability over the course of the study;
  • Lower quantities of key liver metabolites in the bloodstream than controls as hypothesized, suggesting bypass of first pass liver metabolism.

Study Design Parameters:

The study was designed to principally assess the relative ingestible nicotine absorption performance of DehydraTECHTM-powered formulations compared to concentration-matched control formulations that lacked any form of delivery enabling technology in rats. Nicotine was administered in a nicotine polacrilex derivative format as is widely commercialized today in nicotine replacement therapy products such as chewing gums. Twelve male rats were divided into four groups of three, such that DehydraTECHTM and control formulations were each tested at a 1 mg/Kg and 10 mg/Kg dosage level. Formulations were administered orally and all rats were cannulated for blood collection at multiple intervals over an 8-hour duration post-dosing with the first data collection at the 15-minute mark. Urine and feces were also collected for up to a 24-hour duration post-dosing, and essential organ tissue samples were also collected for examination after the study. All samples were subjected to analytical testing in order to quantify the levels of nicotine therein, as well as the levels of three major liver metabolites thereof, hydroxycotinine, nicotine N’-oxide, and cotinine, in order to assess the relative metabolite levels absorbed by the different formulations. Lexaria’s hypothesis was tested to prove that its DehydraTECHTM technology would influence more rapid and complete intestinal bioabsorption of nicotine lymphatically with less metabolic degradation by the liver. All animals were also assessed for general tolerability of the administered formulations. The study was conducted at the same independent laboratory in Philadelphia where the Company completed its initial cannabidiol absorption study in 2015.

Results & Observations:

The Lexaria formulations generally achieved faster absorption, higher peak absorption and higher overall quantities of nicotine, on average, in the blood than the concentration-matched control formulations at both the 1mg and 10 mg/Kg doses tested. Furthermore, as previously reported, there were no obvious signs of gastrointestinal distress such as vomiting or diarrhea indicating that the animals appeared to tolerate the treatment well.

Nicotine blood levels were evaluated multiple times over a period of 8 hours after dosing. In the 10mg/Kg dosing arm, the control formulation required nearly 3 hours to reach similar levels of blood absorption that the Lexaria formulation reached in only 15 minutes. Furthermore, the Lexaria formulation went on thereafter to demonstrate peak plasma levels that were 148% of those achieved by the control formulation. If replicated in human studies, these findings are suggestive that Lexaria’s technology could prove more effective in elevating blood nicotine levels through edible formats much more quickly and substantially than previously theorized, potentially making ingestible nicotine preparations a viable alternative to today’s available product formats while also leading to a more rapid nicotine craving satiation.

Analysis of the liver metabolites revealed, as expected, that overall levels in the blood of two of the three metabolites studied were higher in the control group than in the Lexaria formulation group at the 10 mg/Kg dose. This result was especially pronounced in the 45-minute to 2-hour time interval post-dosing which is consistent with the expected timing of the release of metabolites in higher quantity into the bloodstream by the liver following normal physiological processing of ingested nicotine with the control preparation, compared to the DehydraTECHTM technology that is believed to elude first pass liver metabolism. The Lexaria formulation also demonstrated lower quantities of nicotine in the rat urine at both doses, which is consistent with the fact that the levels of nicotine in the rat blood remained higher over the duration of the study with the Lexaria formulation than with the control. The study also revealed that the Lexaria formulation at the 10 mg/Kg level achieved up to 5.6-times as much nicotine upon analysis of the rat brain tissue that was recovered with the matching control formulation. These findings together perhaps suggest prolongation of nicotine effectiveness with the Lexaria formulation which may also be beneficial in humans to control cravings over an extended time-period from a single edible nicotine dose.

“We are very pleased with these topline study findings demonstrating excellent tolerability and substantially faster, more potent and bioavailable absorption of nicotine in an ingestible format with our DehydraTECHTM technology than controls,” said John Docherty, President. “This data supports further investigation of the many possible benefits of our DehydraTECHTM technology for nicotine delivery with potential both as a nicotine replacement therapy as well as an alternative product format for regular tobacco users over today’s inhaled options.”

Further analysis of the existing data is required, and additional datasets from the study are still being processed and have not yet been received by Lexaria. New studies are being planned to pursue investigatory leads produced.

Lexaria’s patented DehydraTECH™ technology is focused on improved delivery methodologies of many commonly used active pharmaceutical ingredient (“API”) substances. As such, it provides an additional layer of effectiveness that is designed to harmonize with the intellectual property of third parties. Both patented and generic API substances can utilize Lexaria’s patented technology. Lexaria’s long-term strategy is to partner with the world’s leading firms as they deliver best-of-class products to their existing large consumer groups.

About Lexaria

Lexaria Bioscience Corp. has developed and out-licenses its disruptive delivery technology that promotes healthier ingestion methods, lower overall dosing and higher effectiveness of lipophilic active molecules. Lexaria has multiple patents pending in over 40 countries around the world and has patents granted in the USA and in Australia for utilization of its DehydraTECHTM delivery technology. Lexaria’s technology provides increases in intestinal absorption rates; more rapid delivery to the bloodstream; and important taste-masking benefits, for orally administered bioactive molecules including cannabinoids, vitamins, non-steroidal anti-inflammatory drugs (NSAIDs), nicotine and other molecules.

www.lexariabioscience.com

For regular updates, connect with Lexaria on Twitter (https://twitter.com/lexariacorp) and on Facebook http://tinyurl.com/y8vzcaam

FOR FURTHER INFORMATION PLEASE CONTACT:

Lexaria Bioscience Corp.

Alex Blanchard, Communications Manager
(778) 796-1897

Or

NetworkNewsWire (NNW)
www.NetworkNewsWire.com

FORWARD-LOOKING STATEMENTS

This release includes forward-looking statements. Statements which are not historical facts are forward-looking statements. The Company makes forward-looking public statements concerning its expected future financial position, results of operations, cash flows, financing plans, business strategy, products and services, competitive positions, growth opportunities, plans and objectives of management for future operations, including statements that include words such as “anticipate,” “if,” “believe,” “plan,” “estimate,” “expect,” “intend,” “may,” “could,” “should,” “will,” and other similar expressions are forward-looking statements, including but not limited to: that any additional patent protection will be realized or that patent achievements will deliver material results. Such forward-looking statements are estimates reflecting the Company’s best judgment based upon current information and involve a number of risks and uncertainties, and there can be no assurance that other factors will not affect the accuracy of such forward-looking statements. Factors which could cause actual results to differ materially from those estimated by the Company include, but are not limited to, government regulation and regulatory approvals, managing and maintaining growth, the effect of adverse publicity, litigation, competition, scientific discovery, the patent application and approval process and other factors which may be identified from time to time in the Company’s public announcements and filings. There is no assurance that potential future testing of DehydraTECHTM for delivery of nicotine in humans will deliver results similar to the in vivo rat study or meaningful results at all. There is no assurance that existing capital is sufficient for the Company’s needs or that it will be able to raise additional capital. There is no assurance the Company will be capable of developing, marketing, licensing, or selling edible products containing cannabinoids, nicotine or any other active ingredient. There is no assurance that any planned corporate activity, scientific research or study, business venture, technology licensing pursuit, patent application or allowance, consumer study, or any initiative will be pursued, or if pursued, will be successful. There is no assurance that any of Lexaria’s postulated uses, benefits, or advantages for the patented and patent-pending technology will, in fact, be realized in any manner or in any part. No statement herein has been evaluated by the Food and Drug Administration (FDA). Lexaria-associated products are not intended to diagnose, treat, cure or prevent any disease.

The CSE has not reviewed and does not accept responsibility for the adequacy or accuracy of this release.

SOURCE: Lexaria Bioscience Corp.

The post Lexaria Achieves Significant Breakthrough in Alternative Nicotine Delivery Technology appeared first on CannabisFN.

Choom™ secures cannabis retail opportunities in Alberta, Saskatchewan and British Columbia

VANCOUVERApril 17, 2018 /PRNewswire/ – Choom™ (CSE: CHOO; OTCQB: CHOOF) (the “Company” or “Choom”) an emerging, fully-integrated cannabis company, is pleased to announce that it has advanced the build-out of its cannabis retail store network.

Choom Holdings Inc. (CNW Group/Choom Holdings Inc.)

Choom™ has applied to Saskatchewan Liquor and Gaming Authority (“SLGA”) for cannabis retail permits in 32 Zones across the province. The SLGA has made 51 cannabis retail permits available in 32 zones through a Request for Proposal process and is expected to award the permits via lottery by June, 2018.

Additionally, Choom™ has secured the rights to 16 retail locations in Alberta and British Columbia, in all cases, subject to all necessary governmental approvals being granted. This number is excepted to grow over the coming months as the Company is currently negotiating additional leases with the intention of submitting applications for retail licenses.

“This is a significant step towards delivering the Choom™ experience of ‘good times with good friends’ for Canadians across the country,” states Choom’s president and CEO, Chris Bogart. “We have now established a footprint to position Choom™ as a leading private cannabis retailer in Western Canada. We will continue to pursue retail licensing opportunities across the country and remain committed to serving all Canadians in the coming consumer cannabis market. Choom’s vision of delivering an elevated customer experience through our curated retail environments, with the creation of modern, stylish storefronts is well underway.”

RETAIL OVERVIEW

Alberta

  • 9 retail locations secured, and applications submitted

Saskatchewan

  • 32 applications submitted

British Columbia

  • 7 retail locations secured

SAY HELLO TO CHOOM™
Choom™ was created for and inspired by the Choom Gang; a group of buddies in Honolulu during the 1970’s who loved to smoke weed—or as the locals called it, “Choom”. Now, after four decades, Choom™ is bringing the spirit of Hawaii to Canada. Choom™ is focused on delivering an elevated customer experience through our curated retail environments, high-grade handcrafted Cannabis supply, and a diversity of brands for the Canadian recreational consumer.

We’re planting our flag in the rapidly growing legal cannabis industry in Canada with our own brand of high-grade handcrafted herb.

www.choom.ca

“Chris Bogart”
President & CEO

Cautionary Statement:

NEITHER THE CANADIAN SECURITIES EXCHANGE NOR ITS REGULATIONS SERVICES PROVIDER HAVE REVIEWED OR ACCEPT RESPONSIBILITY FOR THE ADEQUACY OR ACCURACY OF THIS RELEASE.

Forward-looking information             
This news release contains forward-looking information relating to the Company’s proposed activities and other statements that are not historical facts. Forward-looking information relates to management’s future outlook and anticipated events or results, and include statements or information regarding the plans to obtain directly or through acquisition cannabis retail opportunities, expected governmental approvals for cannabis retail stores, and the general prospects or plans for a cannabis retail network. Although management of the Company has attempted to identify important factors that could cause actual results to differ materially from those contained in forward looking information, there may be other factors that cause results not to be as anticipated, estimated or intended. These factors include risks and uncertainties associated with the results of diligence investigations, developments in the cannabis sector, delays resulting from or inability to obtain required regulatory approvals and ability to access sufficient capital from internal and external sources, reliance on key personnel, regulatory risks and delays and other risks and uncertainties discussed in the management discussion and analysis section of the Company’s interim and most recent annual financial statement or other reports and filings, including the Company’s Listing Statement, made with the applicable Canadian securities regulators. There can be no assurance that such information will prove to be accurate, as actual results and future events could differ materially from those anticipated in such statements. Accordingly, readers should not place undue reliance on forward looking information.

Cision View original content with multimedia:http://www.prnewswire.com/news-releases/choom-secures-cannabis-retail-opportunities-in-alberta-saskatchewan-and-british-columbia-300631184.html

SOURCE Choom Holdings Inc.

 

Source: PR Newswire (April 17, 2018 – 8:00 AM EDT)

The post Choom™ secures cannabis retail opportunities in Alberta, Saskatchewan and British Columbia appeared first on CannabisFN.

Future Farm’s Strategic Partner BCWC, LLC Selected as One of 20 Applicants to Receive Priority Certification by the Massachusetts Cannabis Control Commission

Vancouver, British Columbia , April 17, 2018 (GLOBE NEWSWIRE) — Future Farm Technologies Inc. (the “Company” or “Future Farm”) (CSE: FFT) (OTCQX: FFRMF) is pleased to announce that BCWC, LLC (“BCWC”) has been named as one of 20 recipients of Priority Certification by the Massachusetts Cannabis Control Commission (“CCC”). BCWC’s application to enter the recreational marijuana business will therefore be reviewed on an expedited basis.

As previously announced, Future Farm has entered the Massachusetts cannabis market through its strategic partnership with BCWC, formerly known as Bristol County Wellness Center, Inc. BCWC has a special permit from the City of Attleboro and a provisional license from the Department of Public Health to build and operate a 24,700-sq ft. Registered Marijuana Dispensary (“RMD”) that will grow and sell medical marijuana.  Because of that achievement, BCWC had the right to apply, and did so, to the CCC for “Priority Certification.”  Recipients of Priority Certification are exclusively able to file the first round of applications to, among other things, cultivate marijuana for adult use (i.e. recreational use) beginning on April 16.  The CCC announced on April 10th that, out of well over 200 applications for Priority Certification, it granted only 20.  BCWC was one of the 20 recipients of Priority Certification.

Derek Ross, BCWC’s Manager, commented, “We are very proud to be one of only 20 companies chosen. Becoming a leading cultivator and retailer of adult use cannabis in Massachusetts is a key part of the BCWC strategy. We also look forward to contributing to an increase in the Massachusetts cannabis tourism industry, providing the state with revenue, tax dollars, and job growth.”

Mr. William Gildea, CEO of Future Farm commented, “We made the decision to support BCWC because of the experience and professionalism of Derek Ross and his team. Their success in making this very short list of applicants with Priority Certification demonstrates why that decision was a good one.”  He continued, “This development further solidifies our position as one of the first movers in a state that has approved, but not yet implemented, the adult use of cannabis.”

Future Farm’s strong strategic partnership with BCWC includes loaning BCWC $5,003,100 under a Secured Convertible Promissory Note to fund completion of the 24,700 sq ft vertically integrated BCWC facility in Attleboro, as well as active managerial, administrative and operational support.  The Note will convert automatically into a 51% ownership interest in BCWC on the date on which BCWC receives its RMD Certificate from the Commonwealth of Massachusetts.

For further information, contact William Gildea, Director, at (888) 387-3761.

On behalf of the Board,

Future Farm Technologies Inc.

William Gildea, Chairman & CEO

About Future Farm

Future Farm Technologies Inc. is a Canadian company with projects throughout North America including California, Florida and Maryland. The Company’s business model includes developing and acquiring technologies that will position it as a leader in the evolution of Controlled Environment Agriculture (CEA) for the global production of various types of plants, with a focus on cannabis. Future Farm provides scalable, indoor CEA systems that utilize minimal land, water and energy regardless of climate, location or time of year and are customized to grow an abundance of crops close to consumers, therefore minimizing food miles and its impact to the environment. The Company holds an exclusive, worldwide license to use a patented vertical farming technology that, when compared to traditional plant production methods, generates yields up to 10 times greater per square foot of land.  The contained system provides many other benefits including 90% less water, fertilizer and land used, less travel costs, seed to sale security, scalability, consistency due to year-round production, cost control, product safety and purity by eliminating environmental variability.

The Company is also in the business of designing and distributing LED lighting solutions utilizing the COB and MCOB technology. The Company is focused on delivering cost efficient lighting to North America via advanced e-commerce sites the Company owns and operates. LEDCanada.com, which caters to B2B customers, is a supplier of the newest and highest demand LED solutions. The Company also owns and operates COBGrowlights.com, which caters to both large and small agriculture green houses and controlled cultivation centers. 

Neither the Canadian Securities Exchange nor its Market Regulator (as that term is defined in the policies of the Canadian Securities Exchange) accepts responsibility for the adequacy or accuracy of this release. The Canadian Securities Exchange has not in any way passed upon the merits of the proposed transaction and has neither approved nor disapproved the contents of this press release. 

 This news release may include forward-looking statements that are subject to risks and uncertainties. All statements within, other than statements of historical fact, are to be considered forward looking.  Although the Company believes the expectations expressed in such forward-looking statements are based on reasonable assumptions, such statements are not guarantees of future performance and actual results or developments may differ materially from those in forward-looking statements.  Factors that could cause actual results to differ materially from those in forward-looking statements include market prices, exploitation and exploration successes, continued availability of capital and financing, and general economic, market or business conditions.  There can be no assurances that such statements will prove accurate and, therefore, readers are advised to rely on their own evaluation of such uncertainties.  We do not assume any obligation to update any forward-looking statements except as required under the applicable laws.

Contact:
Future Farm Technologies Inc. 
William Gildea - Director
(888) 387-3761
bill@FutureFarmTech.com

Primary Logo

 

Source: GlobeNewswire (April 17, 2018 – 8:00 AM EDT)

The post Future Farm’s Strategic Partner BCWC, LLC Selected as One of 20 Applicants to Receive Priority Certification by the Massachusetts Cannabis Control Commission appeared first on CannabisFN.

SinglePoint Successfully Completes Audit and Starts Process to File Form 10 In Route to Become Fully Reporting

SEATTLE, April 17, 2018 (GLOBE NEWSWIRE) — via OTC PR WIRE–SinglePoint (SING) is pleased to announce the finalization and successful completion of PCAOB corporate audit. SinglePoint has been working side by side with Turner Stone and Company in order to complete the 2016 and 2017 corporate audit and will now take the necessary steps to become fully reporting by filing a Form 10.

Completion of the corporate audit and filing a Form 10 will give SinglePoint access to raise additional capital on better terms for the company. Additionally, the company believes this will open the doors for institutional and family offices to invest in the open market, provide increased investor confidence and improve shareholder value. This will provide the company the means to aggressively continue its acquisition strategy and development of the company’s blockchain and cannabis payment solutions.

“We as management are very excited to have completed the audit. We have already received term sheets from potential capital partners to raise up to $20,000,000 on friendly terms. This is a major step for the company and I am very confident, more so than ever, in the company’s ability to successfully build upon the solid infrastructure we now have. Currently there are three acquisition targets in negotiations. We look forward to closing these deals and continue expansion into the cannabis market,” states Greg Lambrecht CEO SinglePoint.

About SinglePoint, Inc.
SinglePoint, Inc (SING) is a technology and investment company with a focus on acquiring companies that will benefit from the injection of growth capital and technology integration. The company portfolio includes mobile payments, ancillary cannabis services and blockchain solutions. Through acquisitions into horizontal markets, SinglePoint is building its portfolio by acquiring an interest in undervalued companies, thereby providing a rich, diversified holding base. Through its subsidiary company SingleSeed, the company is providing products and services to the cannabis industry.

Connect on social media at: 
https://www.facebook.com/SinglePointMobile
https://twitter.com/_SinglePoint
https://www.linkedin.com/company/singlepoint
For more information visit: www.SinglePoint.com

Forward-Looking Statements
Certain statements in this news release may contain forward-looking information within the meaning of Rule 175 under the Securities Act of 1933 and Rule 3b-6 under the Securities Exchange Act of 1934, and are subject to the safe harbor created by those rules. All statements, other than statements of fact, included in this release, including, without limitation, statements regarding potential future plans and objectives of the Company, are forward-looking statements that involve risks and uncertainties. There can be no assurance that such statements will prove to be accurate and actual results and future events could differ materially from those anticipated in such statements.

Technical complications, which may arise, could prevent the prompt implementation of any strategically significant plan(s) outlined above. The Company undertakes no duty to revise or update any forward-looking statements to reflect events or circumstances after the date of this release.

Corporate Communications Contact:
NetworkNewsWire (NNW)
New York, New York
www.NetworkNewsWire.com
212.418.1217 Office
Editor@NetworkNewsWire.com

The post SinglePoint Successfully Completes Audit and Starts Process to File Form 10 In Route to Become Fully Reporting appeared first on CannabisFN.

US and Canadian Officials Scramble to Solve Marijuana-Impaired Driving Issue

As legal cannabis use, both medicinal and recreational, spreads farther and wider through both Canada and the United States, one public health concern continues to vex those responsible for regulating public safety. In essence, nobody knows what constitutes impaired driving under the influence of cannabis, what blood levels of THC are acceptable, or even how to accurately test those levels and correlate them with impairment. Compounding the problem is the lack of public awareness of the dangers of drugged driving.

Cannabix Technologies (CSE: BLO) (OTC: BLOZF) is tackling a crucial part of the complex issue head on. The company has advanced its Beta 3.0 Cannabix Marijuana Breathalyzer through several stages of development, hoping to solve the issues surrounding accurate and convenient testing of THC levels.

Alcohol vs. Cannabis Impaired Driving

Alcohol-impaired driving is fairly straightforward in terms of testing, and well understood both by the public and by safety officials. Due to years of scientific study and public awareness campaigns, and to the obvious nature of alcohol impairment, everyone recognizes the dangers and knows the legal limits of alcohol use when it comes to driving. Anything more than one drink an hour and you are risking not only your life but the life of others, as well as legal peril. Either the alcohol is in your bloodstream or not, and there are formulas that can be used to determine the rate at which the body metabolizes alcohol.

Cannabis impairment is not as simple, for a variety of reasons. The plant has been illegal for so long that scientific study has been severely lacking. For instance, regulators are just now realizing that THC metabolizes into various forms in the body, some of which are detectable for weeks after using marijuana.

Cannabix issued an update recently stating, “Marijuana contains several cannabinoids in addition to THC. Many of these have shorter half-lives and are metabolized in the body relatively quickly. THC can be detectable in blood for weeks, whereas metabolites such as 11-hydroxy-delta-9-tetrahydrocannabinol and 11-nor-9-carboxy-tetrahydrocannabinol are only detectable for a few hours after consumption of cannabis. The Cannabix FAIMS device has demonstrated the detection of THC and related metabolites in MS (mass spectrometer)-coupled testing. The detection of THC and its metabolites in human breath provides for real-time pharmacokinetic analysis. Such analysis provides a method for the identification of “recency of use” and also provides analysis of frequent users of marijuana who tend to retain THC in their body for longer periods of time, relative to infrequent marijuana users who tend to clear THC from their body more quickly. This data and analysis will be important for an eventual court approved device.”

As the science slowly catches up with reality, conflicting studies have been published regarding how much marijuana use impairs drivers. In fact, the US National Highway Traffic Safety Administration published a study in 2015 indicating that stoned drivers are about as likely to get in a wreck as sober drivers. At the same time, the state of Washington’s Traffic Safety Commission announced that marijuana use doubles the risk of being in a fatal crash. It’s no wonder that public sentiment is much more tolerant of driving while high on cannabis than it is of driving while drunk on alcohol.

Need for Reliable Testing

Regardless of where regulators come down on the issue of acceptable levels of THC and impaired driving, one glaring need remains. Accurate, portable, non-invasive testing is still a fairly elusive target. As Sarah Urfer, president and owner of ChemaTox lab based in Boulder Colorado, put it, “Testing for THC in whole blood isn’t actually that hard. Where the issue comes is with interpretation and roadside testing.”

Last year, the Canadian federal government studied the effectiveness of roadside saliva tests. While the tests were easy to use and non-invasive, their accuracy (especially in cold weather) is questionable at best. In fact, 80% of the positive results came in weather colder than the manufacturers’ recommended temperature range. Even after the saliva test, a blood test is still required for further analysis and more accurate results.

Cannabix Technologies believes it has the answer to this part of the problem. The company’s Cannabix Marijuana Breathalyzer is being developed to work both independently in the field and in the lab when coupled with a mass spectrometer. This is important since confirmation of field tests by lab spectrometry will likely be essential for the tests to meet regulatory standards.

The breathalyzer also incorporates a specialized breath temperature stabilizing component that overcomes issues surrounding testing in cold weather. Without this level of reliability in a variety of temperatures and environments, any testing protocol may well prove useless and subject to legal challenges. Additionally, while waiting for a backup blood test, cannabis blood levels decrease up to 80-90% in the first hour after use but THC is still impacting the brain. Getting the test right the first time, in a laboratory-verifiable manner, is essential to providing the best solution.

The company, law enforcement, politicians, advocates… everyone agrees that there is an urgent need to settle on an acceptable method for roadside cannabis testing as legalization spreads across North America. “We’re in the infancy with this, and it’s very much an unknown since we don’t have the data,” Greenwood Village Colorado Police Chief John Jackson said. “We spent 25 or 30 years figuring out where we were with alcohol, and finally got to breathalyzers. There is no field test for marijuana yet.” Cannabix Technologies may have the answer, stay tuned for further developments.

Disclaimer 

The above article is sponsored content. Emerging Growth LLC, which owns CannabisFN.com and CFN Media, has been hired to create awareness. Please follow the link below to view our full disclosure outlining our compensation: http://www.cannabisfn.com/legal-disclaimer/

The post US and Canadian Officials Scramble to Solve Marijuana-Impaired Driving Issue appeared first on CannabisFN.

Beleave Receives Sales License from Health Canada

Beleave Inc. (“Beleave” or the “Company“) (CSE: BE; OTCQX: BLEVF) is pleased to announce that its wholly-owned subsidiary, Beleave Kannabis Corp., has received its sales license from Health Canada pursuant to the Access to Cannabis for Medical Purposes Regulations (the “ACMPR“).

“We are thrilled to have obtained our sales license from Health Canada,” stated Beleave CEO, Andrew Wnek. “We have remained diligent and focused throughout the process. We are excited to be able to continue to move the company forward as a result of this news.”

The Company also announces that it has granted 200,000 stock options to purchase common shares (the “Options“) to certain members of its board of directors (the “Board“) in accordance with the Company’s stock option plan. Each option is exercisable to purchase one common share of the Company at $3.00 per common share. All Options vest immediately and expire on January 3, 2021. All common share and option issuances are subject to applicable regulatory approvals (including the Canadian Securities Exchange).

About Beleave
Beleave Inc. is a biotech company and Beleave’s wholly-owned subsidiary Beleave Kannabis Corp. (formerly First Access Medical Inc.) is a licensed producer pursuant to the ACMPR. Beleave’s purpose-built facility is located in Hamilton, Ontario.

Forward-Looking Statements

This news release contains “forward-looking information” within the meaning of applicable securities law (“forward-looking statements”). The use of any of the words “plan”, “anticipate”, “continue”, “estimate”, “expect”, “may”, “will”, “project”, “should”, “believe” and other similar words, or statements that certain events or conditions “may” or “will” occur are intended to identify forward-looking information. These statements are only predictions. Although the Company believes that the expectations and assumptions on which the forward-looking information is based are reasonable, undue reliance should not be placed on the forward-looking information because the Company can give no assurance that they will prove to be correct. These risks and uncertainties include, but are not limited to, the Company’s ability to satisfy the conditions associated with its cultivation and sales license, the availability of further financing, consumer interest in its products, competition, regulation, operational and technological risks, and anticipated and unanticipated costs and delays. Since forward-looking information addresses future events and conditions, by its very nature it involves inherent risks and uncertainties. This information speaks only as of the date of this news release. Actual results could differ materially from those currently anticipated due to a number of factors and risks including various risk factors discussed in the Company’s disclosure documents, which can be found under the Company’s profile on www.sedar.com.

The post Beleave Receives Sales License from Health Canada appeared first on CannabisFN.

Maricann Group Inc. Receives Export Permit From Health Canada

TORONTO, April 16, 2018 (GLOBE NEWSWIRE) — Maricann Group Inc. (CSE:MARI) (FRANKFURT:75M) (OTCMKTS:MRRCF)  (“Maricann” or “the Company”), is pleased to announce that on Friday April13th, 2018, its wholly owned subsidiary, Maricann Inc. received an export permit from Health Canada for a shipment of dried cannabis flower to Germany. This is the first export permit that Maricann has received.

Ben Ward, CEO Stated, “This export permit marks another milestone in the Company’s history and an important first, as we continue to build our Company, globally. Our team of regulatory experts, led by VP of Regulatory Affairs, Dr. Alexandre Sibilev in Canada, continues to add value for Maricann shareholders through this and previous successes, demonstrating a solid track record in moving through regulatory processes. Our team has expert insight, understanding, and expertise in maintaining our existing licenses, whilst progressing in new geographies with their track record of applied expertise. Export of cannabis from Canada is an important pillar of our near-term strategy, combined with eventual in country production in new geographies, where and when permitted.”

The Company is established in Germany, with operations for its two 95% owned subsidiaries, Maricann GmbH (THC cannabis) and Mariplant GmbH (non-THC cannabis) centred at its campus in Ebersbach, Germany (between Leipzig and Dresden).  The Company is represented in both Maricann and Mariplant by full time established professionals in the pharmaceutical production and agricultural sectors, respectively.

About Maricann Group Inc.

Maricann is a vertically integrated producer and distributor of marijuana for medical purposes. The company was founded in 2013 and is based in Burlington, Ontario, Canada and Munich, Germany, with production facilities in Langton, Ontario, Canada where it operates a medicinal cannabis cultivation, extraction, formulation and distribution business under federal licence from the Government of Canada, and Dresden, Saxony, Germany. Maricann is currently undertaking an expansion of its cultivation and support facilities in Canada in a 942,000 sq. ft. (87,515 sq. m) build out, with a designed expected capacity of producing 95,000 kg (based on conservative estimates) of dry cannabis flower per year to support existing and future patient growth.

For more information about Maricann, please visit our website at www.maricann.com

Forward Looking Information

Certain statements in this document, including, without limitation, statements with respect to  the future designed production capacity of Maricann’s expanded facility and other subjects, contain forward-looking statements which can be identified by the use of forward-looking terminology such as “believes”, “expects”, “may”, “desires”, “will”, “should”, “projects”, “estimates”, “contemplates”, “anticipates”, “intends”, or any negative such as “does not believe” or other variations thereof or comparable terminology. No assurance can be given that potential future results or circumstances described in the forward-looking statements will be achieved or will occur. By their nature, these forward-looking statements, necessarily involve risks and uncertainties, including those discussed herein, that could cause actual results to significantly differ from those contemplated by these forward-looking statements. Such statements reflect the view of the Company with respect to its operations, expansion project and other future events, and are based on information currently available to the Company and on assumptions, which it considers reasonable. In the case of the Company’s expected designed production capacity for its expansion project facility, the expectations of management are based on the designs and plans of the new facility and assumes it will be successfully completed, licensed and operate as planned.  Management cautions readers that the assumptions relative to the future events, several of which are beyond Management’s control, could prove to be incorrect, given that they are subject to certain risk and uncertainties, and that actual results may differ materially from those projected. Factors which could cause results or events to differ from current expectations include, among other things: fluctuations in operating results; the impact of general economic, industry and market conditions; the ability to recruit and retain qualified employees; fluctuations in cash flow; increased levels of outstanding debt and obligations under a capital lease; failure to obtain all necessary regulatory approvals; risks inherent to building and bringing into production new facilities;  uncertainties with respect to estimated production capacity based on designs and plans; expectations regarding market demand for particular products and the dependence on new product development; the impact of market change; and the impact of price and product competition and other risks identified in the Company’s latest annual information form and other disclosure documents filed under its profile at www.sedar.com. Management disclaims any intention or obligation to update or revise any forward-looking statements whether as a result of new information, future events or otherwise, except as required by applicable securities laws. The reader is cautioned not to place undue reliance on forward-looking information.

The Canadian Securities Exchange has not reviewed, approved or disapproved the content of this news release.

CONTACT INFORMATION

Investor Relations
Graham Farrell
Director of Investor Relations
graham@maricann.com
647-643-7665

Corporate Headquarters (Canada)
Maricann Group Inc. (Toronto)
845 Harrington Court, Unit 3
Burlington Ontario L7N 3P3
Canada
289-288-6274

Primary Logo

 

Source: GlobeNewswire (April 16, 2018 – 8:47 AM EDT)

The post Maricann Group Inc. Receives Export Permit From Health Canada appeared first on CannabisFN.

Cannabix Technologies Files FAIMS Cannabis Detection Patent – Enters into License Agreement with University of Florida and Provides Technology Update

The Cannabix Marijuana Breathalyzer is being developed to give law enforcement and employers a tool to enforce public safety

VANCOUVER, British Columbia, April 16, 2018 (GLOBE NEWSWIRE) — Cannabix Technologies Inc. (CSE:BLO) (OTC PINK:BLOZF) (the “Company or Cannabix”) developer of the Cannabix Marijuana Breathalyzer for law enforcement and the workplace, is pleased to report it has filed a Patent Cooperation Treaty (“PCT”) application titled, “Device and Method for Detection of Cannabis and Other Controlled Substances Using FAIMS” (PCT/CA2017/000042). This PCT covers intellectual property related to earlier versions of the Cannabix Marijuana Breathalyzer. Under its relationship with the University of Florida (“the University”), the Company has entered into a second license agreement with the University for PCT application CA2017/000042. The agreement provides Cannabix exclusive worldwide rights in the area of breath analysis of controlled substances. Cannabix is developing an innovative FAIMS (field asymmetric waveform ion mobility spectrometry) based instrument for the detection of ∆9-tetrahydrocannabinol in human breath.

In recent months the Company has been characterizing its Beta 3.0 Cannabix Marijuana Breathalyzer prototype performance measures both independently and coupled to a mass spectrometer (MS), in preparation for expanded field testing. This work has led to the design and development of several improvements to the device which are now being incorporated. The characterizing work has focussed on better separation of several analytes in human breath that are similar in molecular mass and geometry to THC. Testing has included further temperature characterization and flow control. A unique gating system has been developed that allows switching between the standalone FAIMS detector and a conventional MS enabling rapid alternation between both mechanisms during a single breath, proving enhanced analysis capability.

THC and related metabolite characterization

Marijuana contains several cannabinoids in addition to ∆9-tetrahydrocannabinol (“THC”). Many of these have shorter half-lives and are metabolized in the body relatively quickly. THC can be detectable in blood for weeks, whereas metabolites such as 11-hydroxy-delta-9-tetrahydrocannabinol and 11-nor-9-carboxy-tetrahydrocannabinol are only detectable for a few hours after consumption of cannabis. The Cannabix FAIMS device has demonstrated the detection of THC and related metabolites in MS-coupled testing. The detection of THC and its metabolites in human breath provides for real-time pharmacokinetic analysis. Such analysis provides a method for the identification of “recency of use” and also provides analysis of frequent users of marijuana who tend to retain THC in their body for longer periods of time, relative to infrequent marijuana users who tend to clear THC from their body more quickly. This data and analysis will be important for an eventual court approved device, furthermore, 11-nor-9- carboxy-tetrahydrocannabinol is the primary metabolite from the liver, which is prevalent from the consumption of edibles. Cannabix scientists are working quickly to complete this characterization stage.

The Company also reports that it has renewed its ongoing research agreement for 2018 with the Dr. Yost lab at the University of Florida.

About Cannabix Technologies Inc.

Cannabix Technologies Inc. is a leader in marijuana breathalyzer development for law enforcement and the workplace. Cannabix has established breath testing technologies in the pursuit of bringing durable, portable hand-held tools to market to enhance detection of marijuana impaired driving offences on roads at a time when marijuana is becoming legal in many global jurisdictions. Cannabix is working to develop drug-testing devices that will detect THC- the psychoactive component of marijuana that causes intoxication- using breath samples. In particular, Cannabix is focused on developing breath testing devices for detection of recent use of THC, in contrast to urine testing for THC metabolite that requires an invasive collection and reflects usage, days or even weeks earlier. The devices will also be useful for other practical applications such as testing employees in the workplace where impairment by THC can be hazardous.

We seek Safe Harbor.

On behalf of the Board of Directors

“Rav Mlait”

CEO
Cannabix Technologies Inc.

For further information, contact the Company at info@cannabixtechnologies.com

The CSE has not reviewed and does not accept responsibility for the adequacy or accuracy of this release.

Cautionary Statement Regarding Forward-Looking Statements

This press release contains forward-looking information that involves various risks and uncertainties regarding future events. Such forward-looking information can include without limitation statements based on current expectations involving a number of risks and uncertainties and are not guarantees of future performance of the Company, such as final development of a commercial or prototype product(s), successful trial or pilot of company technologies, no assurance that commercial sales of any kind actually materialize; no assurance the Company will have sufficient funds to complete product development. There are numerous risks and uncertainties that could cause actual results and the Company’s plans and objectives to differ materially from those expressed in the forward-looking information, including: (i) adverse market conditions; (ii) risks regarding protection of proprietary technology; (iii) the ability of the Company to complete financings; (iv) the ability of the Company to develop and market its future product; and (v) risks regarding government regulation, managing and maintaining growth, the effect of adverse publicity, litigation, competition and other factors which may be identified from time to time in the Company’s public announcements and filings. There is no assurance that the marijuana breathalyzer business will provide any benefit to the Company, and no assurance that any proposed new products will be built or proceed. There is no assurance that existing “patent pending” technologies licensed by the Company will receive patent status by regulatory authorities.  The Company is not currently selling commercial breathalyzers. Actual results and future events could differ materially from those anticipated in such information. These and all subsequent written and oral forward-looking information are based on estimates and opinions of management on the dates they are made and are expressly qualified in their entirety by this notice. Except as required by law, the Company does not intend to update these forward-looking statements.

Primary Logo

 

Source: GlobeNewswire (April 16, 2018 – 8:45 AM EDT)

The post Cannabix Technologies Files FAIMS Cannabis Detection Patent – Enters into License Agreement with University of Florida and Provides Technology Update appeared first on CannabisFN.

FinCanna Comments on President Trump’s Hands-Off Approach to Legalized Marijuana

VANCOUVER, British Columbia, April 16, 2018 (GLOBE NEWSWIRE) — FinCanna Capital Corp. (“FinCanna”) (CSE:CALI) (OTCQB:FNNZF) is pleased to report that an article published on Friday by the Washington Post, stated “President Trump has promised a top Senate Republican (Senator Cory Gardner) that he will support congressional efforts to protect states that have legalized marijuana.”

Senator Gardner, was quoted in the article as saying, “Furthermore, President Trump has assured me that he will support a federalism-based legislative solution to fix this states’ rights issue once and for all.”

The article also states, “A bill has not been finalized, but Gardner has been talking quietly with other senators about a legislative fix that would, in effect, make clear the federal government cannot interfere with states that have voted to legalize marijuana.”

FinCanna, which is building a diversified portfolio of royalty investments in scalable, best-in-class projects and companies in U.S states where cannabis has been legalized, is strongly positioned to benefit from advancements in federal legislation.

Andriyko Herchak, CEO and President of FinCanna comments, “While a bill has not yet been finalized, we feel these words of commitment from President Trump to a hands-off approach on states that legalized marijuana is extremely positive and should continue to create further comfort and momentum for investors looking to be a part of the licensed cannabis movement in the United States.”

A link to the full article published by the Washington Post can be found here.

About FinCanna

FinCanna provides financing to top-tier companies in the licensed medical cannabis industry in exchange for a royalty on revenues. FinCanna, led by a team of finance and industry experts, is building its diversified portfolio of royalty investments in scalable, best-in-class projects and companies in U.S. legal states, with a focus on California. For additional information visit www.fincannacapital.com and FinCanna’s profile at www.sedar.com.

FinCanna Capital Corp.
Andriyko Herchak, CEO & Director

Investor Relations:

Arlen Hansen
Kin Communications
1-866-684-6730
CALI@kincommunications.com

Forward-Looking Information
Information set forth in this news release may involve forward-looking statements under applicable securities laws. Forward-looking statements are statements that relate to future, not past, events. In this context, forward-looking statements often address expected future business and financial performance, and often contain words such as “anticipate”, “believe”, “plan”, “estimate”, “expect”, and “intend”, statements that an action or event “may”, “might”, “could”, “should”, or “will” be taken or occur, or other similar expressions. All statements, other than statements of historical fact, included herein including, without limitation, statements about CTI’s future production and how the developing U.S. legal regime will impact the cannabis industry.  By their nature, forward-looking statements involve known and unknown risks, uncertainties and other factors which may cause the actual results, performance or achievements, or other future events, to be materially different from any future results, performance or achievements expressed or implied by such forward-looking statements. Such factors include, among others, the risks identified in the CSE listing statement and other reports and filings with the applicable Canadian securities regulators. Forward-looking statements are made based on management’s beliefs, estimates and opinions on the date that statements are made, and the respective companies undertakes no obligation to update forward-looking statements if these beliefs, estimates and opinions or other circumstances should change, except as required by applicable securities laws. Investors are cautioned against attributing undue certainty to forward-looking statements. The Company assumes no responsibility to update or revise forward-looking information to reflect new events or circumstances unless required by applicable law.

Primary Logo

 

Source: GlobeNewswire (April 16, 2018 – 3:05 AM EDT)

The post FinCanna Comments on President Trump’s Hands-Off Approach to Legalized Marijuana appeared first on CannabisFN.

Pivot Pharmaceuticals Terminates Letter of Intent for the Acquisition of Agro-Biotech

VANCOUVERApril 16, 2018 /CNW/ – Pivot Pharmaceuticals Inc. (CSE: PVOT / OTCQB: PVOTF / FRA: NPAT) (“Pivot” or the “Company”) reports that it has terminated the previously announced letter of intent that it had entered into for the acquisition of Agro-Biotech.

“Despite our extensive efforts, we have been unable to complete the acquisition of Agro-Biotech in accordance with the terms and conditions initially agreed upon by the parties. While we are extremely disappointed with this outcome, Pivot continues to pursue other value-enhancing opportunities for the Company and its shareholders,” said Patrick Frankham, CEO of Pivot.

Pivot is currently reviewing the legal alternatives available to it to obtain recovery from Agro-Biotech of the amounts expended by it in the pursuit of this transaction, as well as further damages resulting from the non-completion of the transaction.

About Pivot Pharmaceuticals Inc.

Pivot Pharmaceuticals Inc. is a biopharmaceutical company engaged in the development and commercialization of therapeutic pharmaceuticals and nutraceuticals using innovative drug delivery platform technologies. Pivot’s wholly-owned medical cannabis products division, Pivot Green Stream Health Solutions Inc. (“PGS” or “Pivot Green Stream”), conducts research, development and commercialization of cannabinoid-based nutraceuticals and pharmaceuticals. PGS has acquired “RTIC” Ready-To-Infuse Cannabis powder to oil technology, BiPhasix™ Transdermal Drug Delivery platform technology (topical), Solmic Solubilisation technology (oral) and Thrudermic Transdermal Nanotechnology (transdermal) for the delivery and commercialization of cannabinoid, cannabidiol (CBD), and tetrahydrocannabinol (THC)-based products. PGS’ initial product development candidates will include topical treatments for women’s sexual dysfunction (PGS-N005), as well as psoriasis (PGS-N007), and an oral product (PGS-N001) for cancer supportive care. For more information please visit www.pivotpharma.com

Cautionary Statement

Certain information in this news release constitutes forward-looking statements under applicable laws. Any statements that are contained in this news release that are not statements of historical fact may be deemed to be forward-looking statements that involve certain risks and uncertainties that could cause actual results to differ from those in the forward-looking statements. Words such as anticipate, believe, estimate, expect, intend, and similar expressions, as they relate to Pivot, Pivot Green Stream or their respective management, identify forward-looking statements. Forward looking statements are based on certain assumptions regarding the Company, including expected growth, results of operations, performance, industry trends, growth opportunities and potential recoveries from Agro-Biotech. While the Company considers these assumptions to be reasonable, based on information currently available, they may prove to be incorrect. Readers are cautioned not to place undue reliance on forward-looking statements. Forward-looking statements also necessarily involve known and unknown risks, including, without limitation, risks associated with general economic conditions; adverse industry events; marketing costs; loss of markets; future legislative and regulatory developments involving medical marijuana; inability to access sufficient capital from internal and external sources, and/or inability to access sufficient capital on favourable terms; the medical marijuana industry in Canada generally, income tax and regulatory matters; the ability of the Company to implement its business strategies; competition; crop failure; currency and interest rate fluctuations and other risks. Readers are cautioned that the foregoing list is not exhaustive. Readers are further cautioned not to place undue reliance on forward-looking statements as there can be no assurance that the plans, intentions or expectations upon which they are placed will occur. Such information, although considered reasonable by management at the time of preparation, may prove to be incorrect and actual results may differ materially from those anticipated. Forward-looking statements contained in this news release are expressly qualified by this cautionary statement.

Cision View original content:http://www.prnewswire.com/news-releases/pivot-pharmaceuticals-terminates-letter-of-intent-for-the-acquisition-of-agro-biotech-300630255.html

SOURCE Pivot Pharmaceuticals Inc.

View original content: http://www.newswire.ca/en/releases/archive/April2018/16/c6901.html

Pivot Pharmaceuticals Inc., Patrick Frankham, PhD, MBA, Chief Executive Officer, Tel: (514) 943-1899, Email: Info@PivotPharma.com; Virtus Advisory Group, Investor Relations, Email: pivot@virtusadvisory.com, Tel: + (416) 644-5081Copyright CNW Group 2018

 

Source: Canada Newswire (April 16, 2018 – 8:57 AM EDT)

The post Pivot Pharmaceuticals Terminates Letter of Intent for the Acquisition of Agro-Biotech appeared first on CannabisFN.

Trump Reverses Policy on Cannabis Legalization

President Trump has been notoriously unpredictable when making policy decisions – in fact unpredictability might be his primarily policy doctrine. The appointment of Jeff Sessions as Attorney General and the rescinding of the Cole Memo were widely viewed as anti-legalization moves by the Trump administration, despite widespread approval for legalization among voters in the nine states that have legalized marijuana thus far.

But, in an unexpected turn of events, comments made last week to Sen. Cory Gardner (R-Co.) suggest that the president supports a law to allow state legalization experiments to continue.

“President Trump has consistently supported states’ rights to decide for themselves how to best approach marijuana,” said Sen. Gardner in a press release last week. “Late Wednesday, I received a commitment from the President that the Department of Justice’s rescission of the Cole memo will not impact Colorado’s legal marijuana industry. Furthermore, President Trump has assured me that he will support a federalism-based legislative solution to fix this states’ rights issue once and for all.”

Sen. Gardner had previously threatened to block any Department of Justice nominations until he received such reassurances from the Trump administration about marijuana. With the new assurances from the president, Sen. Gardner announced that he would lift its remaining holds on Department of Justice nominees and work diligently on a bipartisan legislative solution that can pass Congress and head to the President’s desk to deliver on his position.

According to the Washington Post, White House officials confirmed that Sen. Gardner’s statements were accurate, but the Justice Department has declined to comment. The lack of support from the Justice Department has sparked some concern that the president may be unable or unwilling to deliver on his promise. These sentiments have left many analysts cautiously optimistic, but still unsure about the industry’s future.

That said, it’s possible that President Trump has reversed his decisions amid widespread and growing support for cannabis legalization. According to Gallup, more than 64 percent of Americans support marijuana legalization, which is up from just 12 percent around 1970.

The cannabis industry will be keeping a close eye on this legislative agenda over the coming months, as any move by Congress could provide meaningful legal support for companies operating in the space and potentially access to the banking sector.

Cannabis stocks rose more than 10 percent on Friday following the news, reversing recent declines, and could mark the beginning of a renewed uptrend.

The post Trump Reverses Policy on Cannabis Legalization appeared first on CannabisFN.

Maricann Group Announces Definitive Agreement for Haxxon Acquisition

TORONTO, April 13, 2018 (GLOBE NEWSWIRE) — Maricann Group Inc. (CSE:MARI) (FRANKFURT:75M) (OTCMKTS:MRRCF)  (“Maricann” or “the Company”) is pleased to announce it has entered into a definitive agreement with respect to the acquisition of all outstanding shares of Haxxon AG (“Haxxon”).  The acquisition of Haxxon forms a critical element of the Company’s European expansion strategy.  When complete, the acquisition will allow Maricann to enter the Swiss market through Haxxon’s production of feminized high CBD cannabis plants.  Haxxon operates within a 6,000 sq. m. (~64,500 sq. ft.) indoor facility in Regensdorf, Switzerland, an industrial suburb of Zurich, located less than 10 minutes from the airport.

CEO Ben Ward commented: “Maricann will enhance Haxxon’s existing operations by investing 4,800,000 CHF to improve existing cultivation facilities, improving yield, then add extraction and post-processing capabilities to create finished products for inhalation as a tobacco substitute.   These products will comply with both Swiss and European law with THC below 1% for the local market, and THC below 0.2% for the broader European market.”

Chief Scientific Officer Steven Bennett, PhD. stated earlier: “Indoor cultivation of high-quality Cannabis sativastrains (hemp) allows us to optimally control the environment to express and preserve the cannabinoid and terpenoid profiles desired for inhalation, which is not easily achieved with outdoor hemp. The cultivation of high CBD strains requires attention similar to high THC strains. In both cases, the best starting materials are required to make the most effective and sought-after products.”

The transaction is scheduled to close on or about May 15th, 2018, or as soon as possible, subject to regulatory approval and the approval of the holders of the Company’s 9% secured convertible debentures holding 66 2/3% in principal amount of the outstanding debentures being obtained by no later than May 31, 2018. Haxxon is being acquired for CHF 2,000,000 in cash and CHF 6,000,000 in common shares of the Company at the 20-day VWAP ending two trading days before closing.

About Maricann Group Inc.

Maricann is a vertically integrated producer and distributor of marijuana for medical purposes. The company was founded in 2013 and is based in Burlington, Ontario, Canada and Munich, Germany, with production facilities in Langton, Ontario, Canada where it operates a medicinal cannabis cultivation, extraction, formulation and distribution business under federal licence from the Government of Canada, and Dresden, Saxony, Germany. Maricann is currently undertaking an expansion of its cultivation and support facilities in Canada in a 942,000 sq. ft. (87,515 sq. m) build out, with a designed expected capacity of producing 95,000 kg (based on conservative estimates) of dry cannabis flower per year to support existing and future patient growth.

For more information about Maricann, please visit our website at www.maricann.com

Forward Looking Information

Certain statements in this document, including, without limitation, statements with respect to Haxxon, its future activities, including cultivation of feminized low THC cannabis plants, the transaction, the future designed production capacity of Maricann’ expanded facility and other subjects, contain forward-looking statements which can be identified by the use of forward-looking terminology such as “believes”, “expects”, “may”, “desires”, “will”, “should”, “projects”, “estimates”, “contemplates”, “anticipates”, “intends”, or any negative such as “does not believe” or other variations thereof or comparable terminology. No assurance can be given that potential future results or circumstances described in the forward-looking statements will be achieved or will occur. By their nature, these forward-looking statements, necessarily involve risks and uncertainties, including those discussed herein, that could cause actual results to significantly differ from those contemplated by these forward-looking statements. Such statements reflect the view of the Company with respect to its operations, expansion project, Haxxon, Haxxon’s future activities, the transaction and other future events, and are based on information currently available to the Company and on assumptions, which it considers reasonable. In the case of Haxxon future activities, management has based its statements in part on current and historical activities of Haxxon and assumed its business will be successfully continued, expanded and integrated to Maricann’s business. In the case of the Company’s expected designed production capacity for its expansion project facility, the expectations of management are based on the designs and plans of the new facility and assumes it will be successfully completed, licensed and operate as planned.  Management cautions readers that the assumptions relative to the future events, several of which are beyond Management’s control, could prove to be incorrect, given that they are subject to certain risk and uncertainties, and that actual results may differ materially from those projected. Factors which could cause results or events to differ from current expectations include, among other things: inability for Maricann to integrate Haxxon and realize the benefits of the acquisition of Haxxon, fluctuations in operating results; the impact of general economic, industry and market conditions; the ability to recruit and retain qualified employees; fluctuations in cash flow; increased levels of outstanding debt and obligations under a capital lease; failure to obtain all necessary regulatory approvals; risks inherent to building and bringing into production new facilities;  uncertainties with respect to estimated production capacity based on designs and plans; expectations regarding market demand for particular products and the dependence on new product development; the impact of market change; and the impact of price and product competition and other risks identified in the Company’s latest annual information form and other disclosure documents filed under its profile at www.sedar.com. Management disclaims any intention or obligation to update or revise any forward-looking statements whether as a result of new information, future events or otherwise, except as required by applicable securities laws. The reader is cautioned not to place undue reliance on forward-looking information.

The Canadian Securities Exchange has not reviewed, approved or disapproved the content of this news release.

CONTACT INFORMATION

Investor Relations
Graham Farrell
Director of Investor Relations
graham@maricann.com
647-643-7665

Corporate Headquarters (Canada)
Maricann Group Inc. (Toronto)
845 Harrington Court, Unit 3
Burlington Ontario L7N 3P3
Canada
289-288-6274

European Headquarters (Germany)
Maricann GmbH
Thierschstrasse 3, 80538 Munchen, Deutschland

Primary Logo

 

Source: GlobeNewswire (April 13, 2018 – 9:09 AM EDT)

The post Maricann Group Announces Definitive Agreement for Haxxon Acquisition appeared first on CannabisFN.

Evolve Formulas and Lightshade Join Forces for Week-Long Health and Wellness Initiative

Cannabis Brand and Dispensary to Offer Education and Product Discounts

DENVER (April 11, 2018) – Evolve Formulas, the cannabis brand behind the game-changing transdermal NanoSerum™, will partner with Lightshade, one of Colorado’s premier dispensaries, to kick off a health and wellness-themed week aimed at educating consumers on the non-psychoactive healing benefits of cannabis-infused products. The promotion will take place from April 11th through April 18th across all nine Lightshade locations in Colorado.

As part of the promotional event, Evolve Formulas’ groundbreaking transdermal NanoSerum™ will be featured on sale for buy one, get one for a penny at Lightshade dispensaries.

“Partnering with Lightshade provides us with the opportunity to connect more closely with customers and help them better understand the ways in which smoke-free, non-psychoactive cannabis products can fit into a regular health and wellness regimen,” said David Sutton, COO and President of NanoSphere Health Sciences and Evolve Formulas. “Together, Lightshade and Evolve are advocating for safer, cleaner cannabis consumption, equipping new and seasoned consumers alike with the knowledge they need to make informed decisions and find relief—whether for anxiety, insomnia, chronic pain or inflammation.”

Evolve Formulas recently took home the 2018 Westword Readers’ Choice Award for Best Topicals Company. The company’s pioneering product, transdermal NanoSerum™, is currently available in over 100 dispensaries across Colorado and will launch in California this summer. The gel uses industry-first technology, called the NanoSphere Delivery System™ (NDS), to nano encapsulate cannabis molecules, transporting them through five layers of skin, and into systemic circulation for relief from pain, inflammation, and anxiety in less than ten minutes. NanoSphere Health Sciences, parent company of the Evolve brand, has just received the patent for this groundbreaking technology, giving them ownership over the biggest advancement in non-invasive delivery in over 25 years.

For more information or to schedule an interview, please contact Emily Kielthy at media@nanospherehealth.com or 646-695-7045

NanoSphere’s Commitment to Licensing IP

NanoSphere launched its IP licensing program in 2015 and is entertaining several licensing opportunities via a rigorous evaluation process. For more information about NanoSphere’s licensing program, please visit: https://www.nanospherehealth.com/licensing/

About NanoSphere

NanoSphere Health Sciences LLC, is a biotechnology firm specializing in the creation of the NanoSphere Delivery System™ (NDS), a revolutionary platform using nanotechnology in the biodelivery of supplements, nutraceuticals and over-the-counter medications for the cannabis, pharmaceutical and animal health industries, and beyond. NanoSphere Delivery System™ represents one of the most important developments for advancing the non-invasive and user-friendly delivery of biological agents in over 25 years. For more information on NanoSphere, please visit http://www.nanospherehealth.com.

About Evolve Formulas

Evolve Formulas is the provider of the world’s first and only scientifically proven nanoparticle delivery system in cannabis. Evolve’s pioneering product, transdermal NanoSerum™, is a fast-acting, ultra-strength transdermal formula infused with nano-encapsulated cannabis and cannabis extracts. NanoSerum™ immediately penetrates the skin to deliver direct-focused results and intelligently carries a full spectrum of cannabinoids and phytochemicals to receptors throughout the body for systemic healing. Evolve Formula products leverage NanoSphere Health Sciences™ patent-pending NanoSphere Delivery System™. The NanoSphere Delivery System™ is a revolutionary platform using nanotechnology in the biodelivery of supplements, nutraceuticals and over-the-counter medications for the cannabis, pharmaceutical and animal health industries, and beyond. For more information on Evolve Formulas, visit https://www.evolveformulas.com/. Follow us on Facebook, Instagram and Twitter.

 

The post Evolve Formulas and Lightshade Join Forces for Week-Long Health and Wellness Initiative appeared first on CannabisFN.

Cannabis Giant MedMen Opens the Largest and Most Advanced Cannabis Factory in Nevada

Sparks, Nevada – April 11, 2018 – MedMen, the country’s most recognized cannabis brand, opened a 45,000-square-foot, state-of-art marijuana factory near Reno today, bringing the most advanced cultivation and extraction technology to the state’s fast-growing marijuana industry.

Los Angeles-based MedMen Enterprises, which owns and operates state licensed marijuana facilities in Nevada, California and New York, began construction in late 2016. The company expects the facility to produce approximately 10,000 pounds of high quality cannabis annually, and extracts for edibles and vaporizers. Nevada’s sales are estimated to reach $630 million in annual sales by 2020 according to New Frontier.

“Nevada is an important, strategic market in the nation’s evolving cannabis industry,” said Adam Bierman, Chief Executive and Co-founder of MedMen. “It was one of the first eight states to legalize adult use, and millions of people from all over the world visit the state every year. Getting it right in Nevada is important for the state and for our industry as a whole. We are proud to be setting the bar with what is the most high-tech cannabis facility in the country.” 

Bierman, along with MedMen President and Co-founder Andrew Modlin and several dignitaries attended a ribbon cutting event marking the official opening of the factory. 

“This is the future of cannabis,” Modlin declared as he cut the ribbon.

Attendees toured the factory to learn about its advanced features, including pressurized rooms that control air flow and tissue culture labs to develop healthier crops. The facility will adhere to the highest quality and safety standards in the industry today. MedMen is a contributing member of ASTM International, a global quality and safety standards organization. MedMen has also partnered with LED lighting technology leader Fluence Bioengineering to develop the latest in horticulture lighting. The company will replicate the factory in Desert Hot Springs, CA, and Utica, NY.

The MedMen factory features:

  • A 26,000-square-foot, state-of-the-art greenhouse manufactured in Holland 
  • A tissue culture lab that produces healthier, germ-free plants
  • A flowering room with a 25,000-plant capacity
  • Capable of producing 10,000 pounds annually 
  • Bakery and chocolate kitchen
  • Butane and CO2 extraction rooms 
  • Flash-freeze room to preserve fresh flower
  • High-tech analytics lab

Access video and images from today’s event here.  

MedMen Enterprises is the United States’ preeminent cannabis company with assets and operations in key markets. It is one of the most recognized brands in the cannabis world today. Based in Los Angeles, MedMen employs nearly 700 workers, and is the single largest financial supporter of progressive marijuana laws. 

For more information, visit http://www.medmen.com.

Media Contact:

Briana Chester

Briana.Chester@medmen.com

1-424-465-4419

The post Cannabis Giant MedMen Opens the Largest and Most Advanced Cannabis Factory in Nevada appeared first on CannabisFN.

Technical 420 Interviews Future Farm’s Derek Ross About its Growing Industrial Hemp Business

Vancouver, British Columbia / TheNewswire / April 12, 2018 – Future Farm Technologies Inc. (the “Company” or “Future Farm”) (CSE: FFT) (OTCQX: FFRMF) is pleased to announce a recent Technical 420 interview with Mr. Derek Ross, Future Farm’s partner in its growing industrial hemp business. The interview, published in its entirety, is as follows:

“Today, we have the pleasure of being able to publish an interview with Future Farm’s Derek Ross who has been the key player in the company’s industrial hemp business.

We are excited by this growth vertical and see it as a significant growth driver for the overall company. Derek, it is great to connect with you and we appreciate you being a part of this interview.

Our readers have been very excited by Future Farm’s industrial hemp business and so are we. 2018 has been a major year for Future Farm’s hemp business. Please tell us about the state of current operations and where this emerging growth vertical is going?

I’m excited too! And thank very much for considering me for this interview. We applied for and were granted three industrial hemp licenses in the state of Maine. One license is for our previously announced 120-acre Amity farm, which will be dedicated to feminized seed production during the 2018 season. A second license is for Heresy, Maine where we have entered into a contract with local farmers to lease 100 acres of organic certified land. This farm will be dedicated to organic CBD production. The last license was awarded in Belfast, Maine for our 60,000 sq. ft. facility of which 12.800 sq. ft. is being built out right now. This facility will serve as our processing and production facility where we will germinate over two hundred thousand seedlings and process metric tons of high CBD hemp biomass. In the first phase of the build-out we will be building a propagation space capable of germinating 200,000 seedlings per run. The next phase of the build-out will be our processing and extraction lab, which will be capable of processing over 500 pounds of biomass an hour. In 2018, we are projected to produce 150,000-200,000 pounds of organic, high CBD biomass and harvest over 75,000,000 organic, hemp certified feminized, high CBD seeds. Next year we want to be a resource for local farmers to obtain feminized compliant CBD hemp seeds and be an avenue of distribution for them as well. We truly believe if we can let the farmers do what they do best, which is farm, we can make a significant impact to the agricultural community here in Maine.

Derek, you have an impressive track record of success and have been laser focused on a huge growth initiative. Can you please tell us a little about your background and how you became a leader in the industrial hemp industry?

It all started thirteen years ago when my life became consumed by the cannabis space. I’ve been living and breathing cannabis every day since. Cannabis and hemp are very much similar and when the Farm Bill passed, I saw opportunity. My goal was to develop a strain that would look, smell and grow identical to cannabis but have less than 0.3% THC. It also needed to contain the highest amount of CBD possible and thrive in the northeastern hemisphere. In 2015 I acquired a strain that I was comfortable using as the foundation of this genetic roller coaster ride soon to come. Trial after trial, the THC climbed down into compliance. Roughly a year later after a lot of hard work I had my unicorn. It tested at over 25% CBD and 0% THC. This was ground breaking! Test results like this would yield us double the amount of CBD per acre then any of the average hemp-compliant strains on the market. This strain was the beginning of my industrial hemp career. This year we will stabilize and back breed this strain to produce some of the highest CBD seeds in the world that are feminized, hemp-compliant, and organic.

In the 1930s, Popular Mechanics called industrial hemp a billion-dollar crop. We believe this opportunity is significantly larger due to the known uses of hemp and the incredible applications of it. Can you please tell us how Future Farm plans to take market share in this massive market?

The opportunity is much larger and is growing rapidly. “Cannabis research firm Brightfield Group estimates that the U.S. market for hemp-derived CBD hit $291 million in 2017 and will balloon to $1.65 billion in 2021.” This is growth of more the 500% in only four years!! Future Farm this year will focus on CBD and organically certified, feminized seed production while building infrastructure to participate in other hemp product markets. In 2019, we will switch gears and add two major hemp products that will include the cultivation of CBG, which is an additional cannabinoid found in the cannabis plant and has been gaining serious traction. We also have been exploring industrial hemp fiber production to be utilized in nontoxic, biodegradable child resistant cannabis packaging. The average human throws away 185 pounds of plastic a year. Hemp can fix that.

The future will include genetics specifically grown for individual cannabioids, like CBG and CBN, as well as terpenes, fiber and pulp for clothing, fabrics, paper products, building materials, hemp-based sustainably grown biodegradable plastics. These different genetics will be part of a rotation to be able to produce a variety of products.

Where do you see some of the biggest growth opportunities for Future Farm and what are some potential catalysts for the hemp business.

The biggest growth opportunities for us are right here in the northeast. We want to dig ourselves deep and be an asset to all farmers here in New England, starting with Maine.

A big growth catalyst for hemp is federal legalization. With legislation being introduced to make that happen, I believe Future Farm has positioned itself perfectly.

Senator Mitch McConnell is surprisingly leading a hemp legalization initiative. Can you please tell us a little about this and how it will impact Future Farm’s hemp business?

My hat is off to senator Mitch McConnell. He is a pioneer in the hemp revolution and is rewriting history. If and when it goes federally legal, we will be well-positioned as one of few suppliers of organic feminized CBD seeds with an outlet to farmers who want to include CBD hemp in their crop rotation. Demand for feminized seed is high, selling at an average of $1.00-$1.50/seed. I believe legalizing hemp would only add fuel to our fire.

Do you plan to expand the hemp operations into new markets or continue to focus on the base of operations in Maine?

Maine is our primary focus this year. We believe that the experienced farmers and affordable land make this a viable opportunity. We are excited to provide Maine farmers with the seeds and processing to make them successful, and ultimately drive the Maine economy. Maine is well-known for its local, hand-crafted products and we intend to do our best to support this part of the economy. We look forward to being a part of the ongoing hemp conversation here in Maine.

However, I do see the future to include all of New England, with lots of opportunity to work with our neighbors in VT, NH, MA and CT.

How do you see hemp fitting in to Future Farm’s portfolio-based approach to investing? With the massive addressable market for hemp-based applications can you see the hemp side of the business eventually outpacing the marijuana focused investments?

I see hemp complementing Future Farm’s portfolio approach to cannabis investing. Right now, Future Farm has invested interest in 6 dispensary opportunities and that number is growing. Dispensary sales don’t consist of just THC sales. CBD is a big player in the retail sale revenue as well. Future Farm will be able to utilize its own dispensaries as retail distribution opportunities and at the same time start developing CBD-focused retail brands within these markets. This will give us a seed to retail sale approach and vertically integrate our CBD hemp business. With kilos of CBD concentrates selling for an average of $8,000-$10,000 wholesale and over $35,000 retail we will have an amazing opportunity within our portfolio.

I do love it when a plan comes together and with hemp legalization nearing I do believe that one day very soon the hemp and cannabis revenues will be neck and neck with each other.”

See link to Technical420 article here: https://technical420.com/cannabis-article/future-farm-positions-dominate-industrial-hemp-industry-starting-maine

For further information, contact William Gildea, Director, at (888) 387-3761.

On behalf of the Board,

Future Farm Technologies Inc.

William Gildea, Chairman & CEO

About Future Farm

Future Farm Technologies Inc. is a Canadian company with projects throughout North America including California, Florida and Maryland. The Company’s business model includes developing and acquiring technologies that will position it as a leader in the evolution of Controlled Environment Agriculture (CEA) for the global production of various types of plants, with a focus on cannabis. Future Farm provides scalable, indoor CEA systems that utilize minimal land, water and energy regardless of climate, location or time of year and are customized to grow an abundance of crops close to consumers, therefore minimizing food miles and its impact to the environment. The Company holds an exclusive, worldwide license to use a patented vertical farming technology that, when compared to traditional plant production methods, generates yields up to 10 times greater per square foot of land. The contained system provides many other benefits including 90% less water, fertilizer and land used, less travel costs, seed to sale security, scalability, consistency due to year-round production, cost control, product safety and purity by eliminating environmental variability.

The Company is also in the business of designing and distributing LED lighting solutions utilizing the COB and MCOB technology. The Company is focused on delivering cost efficient lighting to North America via advanced e-commerce sites the Company owns and operates. LEDCanada.com, which caters to B2B customers, is a supplier of the newest and highest demand LED solutions. The Company also owns and operates COBGrowlights.com, which caters to both large and small agriculture green houses and controlled cultivation centers.

Neither the Canadian Securities Exchange nor its Market Regulator (as that term is defined in the policies of the Canadian Securities Exchange) accepts responsibility for the adequacy or accuracy of this release. The Canadian Securities Exchange has not in any way passed upon the merits of the proposed transaction and has neither approved nor disapproved the contents of this press release.

This news release may include forward-looking statements that are subject to risks and uncertainties. All statements within, other than statements of historical fact, are to be considered forward looking. Although the Company believes the expectations expressed in such forward-looking statements are based on reasonable assumptions, such statements are not guarantees of future performance and actual results or developments may differ materially from those in forward-looking statements. Factors that could cause actual results to differ materially from those in forward-looking statements include market prices, exploitation and exploration successes, continued availability of capital and financing, and general economic, market or business conditions. There can be no assurances that such statements will prove accurate and, therefore, readers are advised to rely on their own evaluation of such uncertainties. We do not assume any obligation to update any forward-looking statements except as required under the applicable laws.

Copyright (c) 2018 TheNewswire – All rights reserved.

 

Source: TheNewsWire (April 12, 2018 – 8:00 AM EDT)

The post Technical 420 Interviews Future Farm’s Derek Ross About its Growing Industrial Hemp Business appeared first on CannabisFN.

Spire Secure Logistics provides strategic expertise to provincial government in Canada and announces new Chief Administration Officer

VANCOUVERApril 12, 2018 /CNW/ – Friday Night Inc. (the Company or Friday Night) (CSE: TGIF) (FWB: 1QF) (OTCQB: TGIFF) is pleased to announce that its subsidiary, Spire Secure Logistics (“Spire”), is providing strategic advice and expertise to a Canadian provincial government for the design and implementation of security programs and infrastructure for the legal distribution and sale of cannabis.

Friday Night Inc. (CNW Group/Friday Night Inc.)

Spire is a leading provider of security consultation for the legal cannabis industry and has worked closely with both government and licensed producers to design and build security programs and solutions for the sector. The Company will be working with the provincial government to implement program system protocols for both retail and online sales of cannabis, focusing on the prevention of organized crime infiltration and black market diversion.

Spire’s team of industry experts have amassed more than 50 years’ combined experience in regional, national and international policing and security consultation in a variety of fields. Adding to Spire’s operational enforcement experience, the Company wishes to announce the appointment of Mr. Kevin Mead as Chief Administration Officer and Director International Programs at Spire. Mr. Mead is a 23-year career veteran of the Canadian Army and has served across the country and internationally in numerous command, training and senior staff positions at the tactical, operational and strategic levels. Mr. Mead transitioned as a Commanding Officer of a Canadian Forces Detachment to the BC Ministry of Labour, as an Industrial Relations Officer responsible for legislative compliance and enforcement. Most recently, Mr. Mead served as VP Operations in a private manufacturing firm in the security and defense industry.

Mr. Andrew Richards, CEO of Spire, commented, “We are pleased to be developing secure and compliant strategies and programs as Canadian provinces and cities begin to implement legal cannabis distribution and sales.” He added, “We welcome Kevin to Spire. His expertise in leading inter-agency and multi-disciplinary teams in complex high-risk operations and program delivery is an asset to the team.”

About Friday Night Inc. 

Friday Night Inc. is a Canadian public company, which owns and controls cannabis and hemp-based assets in Las Vegas Nevada as well as an international cannabis and mining security logistics consulting firm. The Company owns 91% of Alternative Medicine Association, LC (AMA), a licensed medical and adult-use cannabis cultivation and production facility that produces its own line of unique cannabis-based products and manufactures other third-party brands.  Infused MFG, also a 91% owned subsidiary, produces hemp-based, CBD products, thoughtfully crafted of high quality organic botanical ingredients. The Company’s wholly-owned subsidiary, Spire Secure Logistics is a leading provider of customized security programs, compliance, information technology, buildout design, and due diligence services for the legal cannabis, mining and investment sectors. Friday Night Inc. is focused on strengthening and expanding its current operations.

Neither the Canadian Securities Exchange nor its Regulation Services Provider (as that term is defined in the policies of the Canadian Securities Exchange) accepts responsibility for the adequacy or accuracy of this release.

Notice regarding Forward Looking Statements: This news release contains forward-looking statements. The use of any of the words “anticipate”, “continue”, “estimate”, “expect”, “may”, “will”, “project”, “should”, “believe” and similar expressions are intended to identify forward-looking statements. Although the Company believes that the expectations and assumptions on which the forward-looking statements are based are reasonable, undue reliance should not be placed on the forward-looking statements because the Company can give no assurance that they will prove to be correct.  Since forward-looking statements address future events and conditions, by their very nature they involve inherent risks and uncertainties. These statements speak only as of the date of this news release. Actual results could differ materially from those currently anticipated due to a number of factors and risks including various risk factors discussed in the Company’s disclosure documents, which can be found under the Company’s profile on www.sedar.com. Friday Night undertakes no obligation to update publicly or revise any forward-looking information, whether as a result of new information, future events or otherwise, except as required by law.

Cision View original content with multimedia:http://www.prnewswire.com/news-releases/spire-secure-logistics-provides-strategic-expertise-to-provincial-government-in-canada-and-announces-new-chief-administration-officer-300628728.html

SOURCE Friday Night Inc.

View original content with multimedia: http://www.newswire.ca/en/releases/archive/April2018/12/c2648.html

Alexia Helgason, Corporate Communications, 604-674-4756 (ext. 1), Alexia@FridayNightInc.comCopyright CNW Group 2018

 

Source: Canada Newswire (April 12, 2018 – 8:30 AM EDT)

The post Spire Secure Logistics provides strategic expertise to provincial government in Canada and announces new Chief Administration Officer appeared first on CannabisFN.

High Hampton Helps Growers Navigate a Complex Market, Plus Exclusive Video Interview

The cannabis industry is projected to reach $50 billion by 2026, according to Cowen & Co., driven by the legalization of adult-use and medical cannabis across a growing number of states. The passage of Proposition 64 in California created one of the largest legal markets in the world, but many smaller growers under Proposition 215 have struggled to keep up with the new policies, while even larger companies continue to face issues at the federal level.

High Hampton Holdings Corp. (CSE: HC) (OTC: HHPHF) (0HCN.F) CEO David E. Argudo has worked on cannabis policy at the local and state levels, as well as internationally in Germany and Columbia. After becoming an elected official in 2009, his first order of business was a dispensary ordinance in his local community. Six months later he became mayor and wrote a letter in favor of taxation – one of the first of its kind back in 2010.

CFN Media recently sat down with Mr. Argudo to discuss the evolution of cannabis policy, how it affects existing growers, and how the company is positioned in the market.

 

California’s Massive Potential

California passed Proposition 215, or the Compassionate Use Act, permitting the use of medical cannabis back in 1996. Qualified patients and caregivers were permitted to possess up to eight ounces of dried marijuana, as long as they possessed a state-issued identification card. Over the ensuing 20+ years, the industry evolved to include many non-profit collectives that grew medical marijuana at scale for patients throughout the state.

In 2016, California passed Proposition 64, or the California Marijuana Legalization Initiative, which aims to create a legalization framework for recreational and medical cannabis. Under these rules, anyone aged 21 or older is permitted to possess and use recreational cannabis. The measure also created two new taxes – on cultivation and retail – and created the basis for statewide and municipal rules governing the production and sale of the drug.

BDS Analytics expects California’s cannabis industry to hit $3.7 billion in 2018 and grow to $5.1 billion in 2019 as more dispensaries come online. As the world’s sixth largest economy, the state is expected to become the single largest cannabis market in the world. Northern California has been the most progressive when it comes to cannabis legalization, but Southern California is quickly catching up and opening up.

The challenge is that many existing growers are finding themselves unprepared for the new framework created by Proposition 64. While they are experienced at growing, many of them lack the expertise in navigating the regulatory requirements of both the state and local authorities, as well as the financial resources necessary to scale up demand and ultimately become successful in a rapidly changing marketplace.

Federal Changes on the Way

Attorney General Jeff Sessions rescinded the Cole Memo back in January, which introduced a lot of uncertainty into the market. In essence, the move put the authority back into the deputy attorney generals’ hands when it comes to cannabis enforcement. Mr. Argudo believes that the move created a lot of noise that spooked investors, but in reality, there’s not much behind the move as most deputy attorney generals recognize the industry’s evolution.

Nearly 20 attorney generals from states with recreational and medical cannabis wrote a letter to Congress in January asking for help with financial regulations. In the letter, the AGs indicated that the grey market made revenue more difficult to track for tax purposes and contributed to a public safety threat as cash intensive businesses are often targets for criminal activity. They requested safe harbor for depository institutions that finance the cannabis industry.

There are also more than 20 other bills in Congress requesting various forms of cannabis legalization and support on a national level. For example, the Marijuana Justice Act seeks to remove medical marijuana from the Controlled Substances List and provide restorative justice to communities disproportionately affected by marijuana arrests and convictions. Bills like these go beyond simple banking issues and address other systemic issues.

Mr. Argudo believes that there is unlikely to be a meaningful change over the next year, but there continues to be real progress in opening up conversations. Just a few years ago, these conversations wouldn’t have even been possible at higher levels of government.

Helping Growers Succeed

High Hampton Holdings Corp. (CSE: HC) (OTC: HHPHF) aims to help experienced growers come into line with the new regulations created by Proposition 64 and ultimately scale their operations into new markets.

The cultivation of cannabis in California requires municipal and state permits to operate, as of January 1, 2018, and many current growers do not meet the standards for these certifications. The state has become increasingly aggressive in shutting down non-compliant operations, while the supply of zoned and permitted areas to cultivate are in high demand. Many experienced growers are losing out to large institutional growers as a result.

High Hampton’s 100% owned CoachellaGro asset is a 10.8 acre property located in the Coachella Cannabis Zone. The company’s management team anticipates receiving a conditional use permit over the near-term, begin construction of the cultivation facilities this year, and begin cultivation as early as the fourth quarter of this year. By working with existing growers, the company aims to capitalize on an existing customers base and help local communities.
For more information, visit the company’s website or download their investor presentation.

Disclaimer

The above article is sponsored content. Emerging Growth LLC, which owns CannabisFN.com and CFN Media, has been hired to create awareness. Please follow the link below to view our full disclosure outlining our compensation: http://www.cannabisfn.com/legal-disclaimer/

The post High Hampton Helps Growers Navigate a Complex Market, Plus Exclusive Video Interview appeared first on CannabisFN.

Emblem Signs 3-Year Supplier Agreement with Fire & Flower

TORONTO, April 11, 2018 (GLOBE NEWSWIRE) — Emblem Corp. (EMC.V) (EMC-WT.V) (“Emblem” or the “Company”), announced today that it has entered into a supplier agreement (the “Agreement”) pursuant to which Emblem, through its wholly owned subsidiary, Emblem Cannabis Corp., will become a preferred cannabis supplier to Fire & Flower Inc. (“Fire & Flower”).

Subject to the approval and subsequent Royal Assent of Bill C-45, the proposed Cannabis Act (Canada) and the receipt by Fire & Flower of all required licensing under the applicable provincial cannabis regimes, pursuant to the Agreement, Emblem will supply Fire & Flower with Emblem branded cannabis products for an initial period of three consecutive years.  It is expected the products will be sold in-store in all provinces in which Fire & Flower operates and, if applicable, in which Emblem has received a provincial listing.

Nick Dean, CEO of Emblem, says the deal presents an incredible opportunity for Emblem to get their adult-use brands into the hands of consumers across Canada. “The retail environment will be critical to generating brand awareness, educating the consumer about products and ultimately driving market share for our adult-use brands,” says Dean. “Today’s deal with Fire & Flower reinforces our belief that the greatest shareholder value will be achieved in the long-run via channels that give the greatest access to consumers. As Fire & Flower is building a leading retail concept in the cannabis space, we anticipate that this arrangement will assist us in our single-minded focus on driving shareholder value.”

“We are excited to enter into this agreement with Emblem. Their awareness of the importance of the retail channel in cannabis as well as their commitment to creating adult-use brands that resonate with consumers aligns well with Fire & Flower’s best-in-class retail cannabis strategy,” explains Trevor Fencott, CEO of Fire & Flower. “There is a lot to accomplish preparing for legalization in Canada, and having partners like Emblem that can move as quickly and decisively as us in the space is definitely an asset.”

Certain directors and officers of Emblem have interests in Fire & Flower. In particular, Harvey Shapiro, a director and the Chairman of the Company, is also a director of Fire & Flower. In addition, Mr. Shapiro owns approximately 19.5% of the common shares of Fire & Flower and controls and directs approximately an additional 65% of the common shares through a voting trust. Further, Maxim Zavet, a director of the Company, owns approximately 4.2% of the common shares of Fire & Flower and Nick Dean, the President and Chief Executive Officer of the Company owns approximately 0.3% of the common shares of Fire & Flower.

Due to the ongoing nature of the negotiations surrounding the Agreement, there will be less than 21 days between the date on which the Company files a material change report with respect to the entering into of the Agreement. The Company considers this is reasonable and necessary in order to ensure the Company’s ability to become a preferred supplier and to obtain the benefits associated with the Agreement.

About Emblem
Emblem Corp., through its wholly-owned subsidiary Emblem Cannabis Corporation, is a fully integrated licensed producer and distributor of medical cannabis and cannabis derivatives in Canada under the ACMPR (Access to Cannabis for Medical Purposes Regulations). Led by a team of cannabis experts and former health care and pharma executives, it has three distinct verticals – cannabis production, patient education centers, and pharmaceutical dosage form development. Emblem trades under the ticker symbol EMC on the TSX Venture Exchange.

About Fire & Flower
Founded by successful cannabis entrepreneurs from the legal Canadian cannabis industry, Fire & Flower is a corporately-owned retail cannabis-lifestyle brand and store concept. Fire & Flower specializes in elevating the Canadian cannabis experience through the thoughtful curation of products, experiential offerings and education-based programming. Fire & Flower is poised to serve customers across the country in Provinces where private retail is permitted.

For further information contact:

Ethan Karayannopoulos
Investor Relations
Emblem Corp.
647.748.9696
ethank@emblemcorp.com

Alex Stojanovic
Chief Financial Officer
Emblem Corp.
416.923.1331
alexs@emblemcorp.com

Chris Bolivar
Vice President, Brand & Marketing
Fire & Flower Inc.
780.903.6782
cbolivar@fireandflower.com

Forward-looking statements

This news release may contain “forward-looking information” and “forward-looking statements” within the meaning of applicable Canadian securities legislation (together, “forward-looking statements”), including statements regarding the Agreement, the successful fulfillment of the Agreement, the Company’s ability to satisfy its obligations under the Agreement, the financial benefit of the Agreement, and the approval of the TSXV. All statements and information contained herein that is not clearly historical in nature may constitute a forward-looking statement. Forward-looking statements are necessarily based upon a number of estimates and assumptions that, while considered reasonable by management, are inherently subject to significant business, economic and competitive risks, uncertainties and contingencies that may cause actual financial results, performance or achievements to be materially different from the estimated future results, performance or achievements expressed or implied by those forward-looking statements.

Forward-looking statements are not a guarantee of future performance and are subject to and involve a number of known and unknown risks and uncertainties, many of which are beyond the control of the Company, which may cause the Company’s actual performance and results to differ materially from any projections of future performance or results expressed or implied by such forward-looking statements. These risks and uncertainties include, but are not limited to, the risks identified in the Company’s annual information form dated October 18, 2017 which has been filed with the Canadian Securities Administrators and is available on www.sedar.com, risks of non-performance by Fire & Flower, the risk that the Company and/or Fire & Flower do not receive the required licenses and permits to perform the obligations under the Agreement and the risk that the proposed operations of Fire & Flower do not conform with the provincial regulatory regime. Any forward-looking statements contained herein are made as of the date hereof and, except as required by law, the Company assumes no obligation to publicly update or revise such statements to reflect new information, subsequent or otherwise.

Readers are cautioned not to put undue reliance on these forward-looking statements. This news release contains information obtained by the Company from third parties and believes such information to be accurate but has not independently verified such information.

Neither the TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in the policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release.

The post Emblem Signs 3-Year Supplier Agreement with Fire & Flower appeared first on CannabisFN.

Naturally Splendid Appoints Douglas Mason as Permanent CEO

VANCOUVER, British Columbia / TheNewswire / April 11th, 2018 — Naturally Splendid Enterprises Ltd. (“Naturally Splendid” or “NSE”) (TSX-V:NSP) (OTCQB:NSPDF) (Frankfurt:50N) announces that further to its January 3rd, 2018 news release, NSE is pleased to announce that after a brief term as interim CEO, NSE has now appointed Mr. Douglas Mason as permanent CEO.

Douglas Mason has over 25 years of experience in the public markets, having served as a senior officer and director for a number of public companies, including 20 years as President and CEO of well-known beverage companies Jolt Cola and Clearly Canadian Beverage Corporation. Doug has been credited as one of the pioneers of the New Age Beverage category. Doug also has extensive experience in financings and acquisitions in capital markets, raising over $200 million over the past 25 years.

Naturally Splendid CEO Mr. Douglas Mason states, “Since stepping in as interim CEO at NSE, we have made a number of tactical and strategic moves that position the company to take advantage of multiple opportunities in the healthy lifestyle market including, food supplements, superfood ingredients, nutraceuticals and cosmeceuticals as well as pet and animal feed markets. With positive steps such as the recent liquidation of our facility in Saskatchewan, securing additional expertise on regulatory matters and product formulation, and beginning the process of our Dealer License application, we are positioning NSE to implement our various strategic initiatives to drive significant growth, most notably in the area of cannabinoid extraction and formulation from cannabis as we anticipate new federal regulations in the Cannabis Act later in 2018.

Mr. Mason adds, “Over my many years of working with consumer goods I have considered myself a pioneer, introducing innovative new product entries and sales methodologies for numerous products including beverages. From consumer-goods and innovative technology to processing opportunities, NSE’s continued path to vertical integration is evidence we are on the right track. Along with the qualified NSE team, my experience with licensing and distribution and introducing new categories to market will be leveraged as we continue to expand our global footprint.”

Naturally Splendid Director and President of the Canadian Hemp Trade Alliance, Russ Crawford states, ‘With the positive vote on the second reading of Bill C-45 in the Senate on March 22, 2018 and Referral to Committee, the implementation of the new Cannabis Act is that much closer. In regard to industrial hemp specifically, we are anticipating the inclusion of a section of the Act referring to industrial hemp specifically allowing for whole plant use and the extraction of cannabinoids such as cannabidiol (CBD) from hemp.

Crawford adds, “NSE is positioning to capitalize on a large number of opportunities inherent in the extreme versatility of industrial hemp as a plant-based protein and omega source, superfood as well as a host of additional applications. Beyond that, if plant utilization legislation will change as we anticipate, NSE can play a meaningful role in supplying raw material for the production of CBD and other extracted cannabinoids as well as retail products containing cannabinoids.”

“We are very excited to appoint Doug; his expertise and consumer-product knowledge will be extremely beneficial to our business and shareholders. Doug has demonstrated exceptional leadership, enthusiasm, a strong commitment to the Company’s success and continual focus on delivering results. For these reasons, we look forward to working together on this compelling opportunity. “states Naturally Splendid President and Director, Craig Goodwin.

Stock Grant

Naturally Splendid, upon approval from the TSX, will be issuing 250,000 common shares to Sead Hamzagic, the chief financial officer of the company.

About Naturally Splendid Enterprises Ltd.

Naturally Splendid is a biotechnology and consumer products company that is developing, producing, commercializing, and licensing an entirely new generation of plant-derived, bioactive ingredients, nutrient dense foods, and related products. Naturally Splendid is building an expanding portfolio of patents (issued and pending) and proprietary intellectual property focused on the commercial uses of industrial hemp and non-psychoactive cannabinoid compounds in a broad spectrum of applications.

  1. (1)BIOTECHNOLOGY – Focused on three major platforms:
  1. (1)Proprietary HempOmega(TM) encapsulation
  1. (2)Extraction and formulation with Cannabidiol (CBD)
  1. (3)Hemp and plant-based proteins.

(2) CONSUMER PRODUCTS –

  • – NATERA(R) – brand of retail hemp and superfood products distributed throughout North America, Asia and Europe.
  • – Prosnack Natural Foods Inc. (Elevate Me(TM)) – lifestyle brand of healthy meal replacement products distributed throughout North America.
  • – Chi Hemp Industries Incorporated (CHII) – e-commerce platform for natural and organic hemp products.
  • – PawsitiveFX(R) – topical pet care products.
  • – NATERA(R)CBD – retail hemp-based cannabinoid nutraceutical and cosmeceutical products distributed in Asia.
  • – NATERA(R)Skincare – brand of retail hemp based cosmeceutical products.

(3) NATERA(R) Ingredients – bulk ingredients including HempOmega(TM).

(4) Co-Packaging/Toll-Processing – packaging for house-brands (NATERA(R) and CHII) and third-party partners.

For more information e-mail info@naturallysplendid.com or call Investor Relations at 604-673-9573

On Behalf of the Board of Directors

Mr. Douglas Mason

CEO, Director

Contact Information

Naturally Splendid Enterprises Ltd.

(NSP – TSX Venture; NSPDF – OTCQB; 50N Frankfurt)

#108-19100 Airport Way

Pitt Meadows, BC, V3Y 0E2

Office: (604) 465-0548

Fax: (604) 465-1128

E-mail: info@naturallysplendid.com

Website: www.naturallysplendid.com

Forward-Looking Statements

Information set forth in this news release contains forward-looking statements that are based on assumptions as of the date of this news release. These statements reflect management’s current estimates, beliefs, intentions and expectations. They are not guarantees of future performance. Naturally Splendid cautions that all forward looking statements are inherently uncertain and that actual performance may be affected by a number of material factors, many of which are beyond Naturally Splendid’s control including, Naturally Splendid’s ability to compete with large food and beverage companies; sales of any potential products developed will be profitable; sales of shelled hemp seed will continue at existing rates or increase; the ability to complete the sales of all bulk hemp seed purchase orders; and the risk that any of the potential applications may not receive all required regulatory or legal approval. Accordingly, actual and future events, conditions and results may differ materially from the estimates, beliefs, intentions and expectations expressed or implied in the forward-looking information. Except as required under applicable securities legislation, Naturally Splendid undertakes no obligation to publicly update or revise forward-looking information.

NEITHER TSX VENTURE EXCHANGE NOR ITS REGULATION SERVICES PROVIDER (AS THAT TERM IS DEFINED IN THE POLICIES OF THE TSX VENTURE EXCHANGE) ACCEPTS RESPONSIBILITY FOR THE ADEQUACY OR ACCURACY OF THIS RELEASE.

Copyright (c) 2018 TheNewswire – All rights reserved.

 

Source: TheNewsWire (April 11, 2018 – 8:30 AM EDT)

The post Naturally Splendid Appoints Douglas Mason as Permanent CEO appeared first on CannabisFN.

Lexaria Bioscience Corp. Receives New U.S. Patent Allowance for Cannabinoid Delivery and Updates Its Expanding Patent Portfolio

KELOWNA, BC / ACCESSWIRE / April 11, 2018 / Lexaria Bioscience Corp. (LXRP) (LXX.CN) (the “Company” or “Lexaria”), a drug delivery platform innovator, announces it has received another new Notice of Allowance from the United States Patent and Trademark Office (“USPTO”) providing claims that protect processes for making specific compositions of matter for enhanced cannabinoid delivery utilizing its DehydraTECH™ technology. This follows Lexaria’s March 22, 2018 press release announcing receipt of the Notice of Allowance for the compositions of matter. These two Notices of Allowance are expected to become Lexaria’s 3rd and 4th granted patents in the US.

Lexaria’s DehydraTECH™ intellectual property portfolio has expanded greatly and now consists of a wide variety of patent families with multiple applications within. Patent applications span compositions and related methods of manufacture and use for Lexaria’s DehydraTECH™ technology with a broad range of lipophilic active substances in foods, beverages, and nutritional supplements, as well as in topical preparations and pharmaceutical dosage forms.

The first patent family is “Food and Beverage Compositions Infused With Lipophilic Active Agents and Methods of Use Thereof”, under which two US patents have been granted, two US patents have been allowed, and multiple patent applications remain pending. Numerous national phase applications have also been filed under the International Patent Cooperation Treaty (“PCT”). One Australian patent has been granted and patent applications are pending in Australia, Canada, China, the European Union, India, and Japan. Original filing dates for this family begin in 2014.

The second patent family is “Methods for Formulating Orally Ingestible Compositions Comprising Lipophilic Active Agents”, under which a US provisional patent application was filed and a PCT filing was based thereon. There is currently one patent application pending in each of the US, Australia, Canada, China, the EU, India, and Japan. Original filing dates for this family begin in 2015.

The third patent family is “Stable Ready-to-Drink Beverage Compositions Comprising Lipophilic Active Agents”, under which a US provisional patent application was filed and a PCT filing was based thereon. There is currently one patent application pending in each of the US, Australia, Canada, China, the EU, India, and Japan. Original filing dates for this family begin in 2016.

The fourth patent family is “Microwave Processing Methods for Formulating Orally Ingestible Compositions Comprising Lipophilic Active Agents”, under which one US provisional patent application is pending and a PCT filing is planned. Original filing dates for this family begin in 2017.

The fifth patent family is “Food and Beverage Compositions Comprising PDE5 Inhibitors”, under which one US provisional patent application is pending and a PCT filing is planned. Original filing dates for this family begin in 2017.

The sixth patent family is “Transdermal Delivery of Lipophilic Active Agents”, under which one US provisional patent application is pending and a PCT filing is planned. Original filing dates for this family begin in 2018.

Lexaria is now managing a portfolio of more than 35 patent applications in over 40 countries around the world and will continue to develop and strengthen its patent portfolio in the USA, Canada, and internationally. New patent application filings for new patent families are planned during 2018 and Lexaria also expects further patent awards this year. As its patent portfolio expands, Lexaria will be better able to commercialize its technologies and defend its intellectual property.

Lexaria’s patented DehydraTECH™ technology is focused on improved delivery methodologies of many commonly used active pharmaceutical ingredient (“API”) substances. As such, it provides an additional layer of effectiveness that is designed to harmonize with the intellectual property of third parties. Both patented and generic API substances can utilize Lexaria’s patented technology. Lexaria’s long-term strategy is to partner with the world’s leading firms as they deliver best-of-class products to their existing large consumer groups.

About Lexaria

Lexaria Bioscience Corp. has developed and out-licenses its disruptive delivery technology that promotes healthier ingestion methods, lower overall dosing and higher effectiveness of lipophilic active molecules. Lexaria has multiple patents pending in over 40 countries around the world and has patents granted in the USA and in Australia for utilization of its DehydraTECHTM delivery technology. Lexaria’s technology provides increases in intestinal absorption rates; more rapid delivery to the bloodstream; and important taste-masking benefits, for orally administered bioactive molecules including cannabinoids, vitamins, non-steroidal anti-inflammatory drugs (NSAIDs), nicotine and other molecules.

www.lexariabioscience.com

For regular updates, connect with Lexaria on Twitter (https://twitter.com/lexariacorp) and on Facebook http://tinyurl.com/y8vzcaam

FOR FURTHER INFORMATION PLEASE CONTACT:

Lexaria Bioscience Corp.
Alex Blanchard, Communications Manager
(778) 796-1897

Or

NetworkNewsWire (NNW)
www.NetworkNewsWire.com

FORWARD-LOOKING STATEMENTS

This release includes forward-looking statements. Statements which are not historical facts are forward-looking statements. The Company makes forward-looking public statements concerning its expected future financial position, results of operations, cash flows, financing plans, business strategy, products and services, competitive positions, growth opportunities, plans and objectives of management for future operations, including statements that include words such as “anticipate,” “if,” “believe,” “plan,” “estimate,” “expect,” “intend,” “may,” “could,” “should,” “will,” and other similar expressions are forward-looking statements, including but not limited to: that any additional patent protection will be realized or that patent achievements will deliver material results. Such forward-looking statements are estimates reflecting the Company’s best judgment based upon current information and involve a number of risks and uncertainties, and there can be no assurance that other factors will not affect the accuracy of such forward-looking statements. Factors which could cause actual results to differ materially from those estimated by the Company include, but are not limited to, government regulation, managing and maintaining growth, the effect of adverse publicity, litigation, competition, scientific discovery, the patent application and approval process and other factors which may be identified from time to time in the Company’s public announcements and filings. There is no assurance that existing capital is sufficient for the Company’s needs or that it will be able to raise additional capital. There is no assurance the Company will be capable of developing, marketing, licensing, or selling edible products containing cannabinoids or any other active ingredient. There is no assurance that any planned corporate activity, scientific research or study, business venture, technology licensing pursuit, patent application or allowance, consumer study, or any initiative will be pursued, or if pursued, will be successful. There is no assurance that any of Lexaria’s postulated uses, benefits, or advantages for the patented and patent-pending technology will in fact be realized in any manner or in any part. No statement herein has been evaluated by the Food and Drug Administration (FDA). Lexaria-associated products are not intended to diagnose, treat, cure or prevent any disease.

The CSE has not reviewed and does not accept responsibility for the adequacy or accuracy of this release.

SOURCE: Lexaria Bioscience Corp.

The post Lexaria Bioscience Corp. Receives New U.S. Patent Allowance for Cannabinoid Delivery and Updates Its Expanding Patent Portfolio appeared first on CannabisFN.

Hydropothecary signs 5-year preferred supplier agreement with SAQ, for an estimated volume of 200,000kg

  • Hydropothecary becomes preferred supplier to Quebec market for a five-year term.
  • Total volume estimated at more than 200,000kg over five-year term
  • Option to extend term for an additional year.
  • Largest supply agreement between an authorized producer and a provincial authority responsible for the supply of cannabis for the adult-use recreational market.

GATINEAU, Québec, April 11, 2018 (GLOBE NEWSWIRE) — The Hydropothecary Corporation (“Hydropothecary” or the “Company”) (TSXV:THCX) is pleased to announce that it has entered into a commercial agreement with the Société des alcools du Québec (SAQ) to be the preferred supplier of cannabis products for the Quebec market for the first five years post-legalization, with an option to extend the term for an additional year.

Under the agreement, Hydropothecary will supply 20,000 kg of products in the first year of the agreement and is expected to supply 35,000 kg in the second year and 45,000 kg in the third. The volumes for the final two years of the agreement will be established at a later date based on the sales generated in the first three years. The supply arrangement covers the full range of the Company’s products and brands, from flowers to cannabis oil.

In the event the volume requirements in years four and five of the agreement amount to 49,500 kg and 54,450 kg respectively based on an anticipated 10% growth rate in both the cannabis market and the Company’s supply requirements under the agreement, and assuming the mix of products supplied moves towards less flower and more value-added products as anticipated, the Company estimates the total volume to be supplied over the five-year term of the agreement could exceed 203,950kg.

The SAQ has the right to terminate the agreement in certain circumstances.

“Becoming the preferred supplier to the Quebec market out of the gate post legalization is a source of great pride and a vote of confidence in our ability to scale operations to meet our supply commitment,” said Sébastien St-Louis, co-founder and CEO of Hydropothecary. “This agreement marks an important step in the execution of our growth strategy, which is focused initially on the Quebec market by expanding our Gatineau facilities and hiring new employees, and then establishing our presence in other Canadian markets.”

“By doing business with Hydropothecary, the SAQ is engaging with a company that complies with the law and adheres to best practices in both corporate governance and the development and manufacturing of high quality and safe products,” added Mr. St-Louis.

Recognizing its responsibility toward Quebec and its citizens, Hydropothecary is committed to:

  • working with the Government of Quebec, the future Société québécoise du cannabis (SQDC), a subsidiary of the SAQ and other partners to implement awareness campaigns promoting responsible cannabis use; and,
  • supporting research and educational programs related to the cultivation and processing of cannabis, as well as the development of medical and recreational cannabis products in Quebec.

Hydropothecary is currently the only cannabis producer in Quebec to hold a license from Health Canada for the sale of cannabis.

The agreement is conditional on the adoption by the federal and provincial governments of the necessary regulatory framework.

Conference call

Hydropothecary will host a conference call for financial analysts and shareholders to discuss the SAQ supply agreement today at 8:30 am EST. The dial-in number is 1-(866) 521-4909, access code is 1776268. A replay of this call will be available afterward on our website www.thcx.com.

About The Hydropothecary Corporation

The Hydropothecary Corporation is an authorized licensed producer and distributor of medical cannabis licensed by Health Canada under the Access to Cannabis for Medical Purposes Regulations. Hydropothecary creates award-winning innovative, easy to use and easy to understand products. Hydropothecary is rapidly increasing its production capacity in the lead-up to recreational adult-use cannabis. Expansion plans will result in a total of 1.3 million sq. ft. of production space, producing 108,000 kg of dried cannabis per year, making Hydropothecary one of the largest producers in the country. Headquartered in Quebec, Hydropothecary is one of the lowest-cost producers in the country.

Forward-Looking Information

This press release contains forward-looking information that is based on certain assumptions and involves known and unknown risks and uncertainties and other factors that could cause actual events to differ materially from current assumptions and expectations. Examples of forward-looking information include, but are not limited to, the Company’s estimates of product volumes to be supplied by it under the supply agreement with the SAQ, its assumptions regarding product mix, its assumption that the agreement will remain in force for its full term and conditional by governments adoption of the necessary regulatory frameworks. These statements should not be read as assurances of future performance or results. Such statements involve known and unknown risks, uncertainties and other factors that may cause actual results, performance or achievements to be materially different from those implied by such statements, including the actual product volumes that will be supplied by the Company under the agreement, the Company’s ability to produce the estimated product volumes, and the actual mix of products that will be supplied and their pricing. A more complete discussion of the risks and uncertainties facing the Company appears in the Company’s Annual Information Form and continuous disclosure filings, which are available on SEDAR’s website at www.sedar.com. Readers are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date of this press release. The Company disclaims any intention or obligation, except to the extent required by law, to update or revise any forward-looking statements as a result of new information or future events, or for any other reason.

Neither the TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in the policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release.

Investor Relations:

Jennifer Smith
Manager of Financial Reporting and Investor Relations
1-866-438-THCX (8429)
invest@THCX.com
www.THCX.com

Media Relations:

Shawn Lyons
Media Relations
Shawn.lyons@thehydropothecary.com

Director

Adam Miron
819-639-5498

Primary Logo

 

Source: GlobeNewswire (April 11, 2018 – 7:00 AM EDT)

The post Hydropothecary signs 5-year preferred supplier agreement with SAQ, for an estimated volume of 200,000kg appeared first on CannabisFN.

InMed Announces Appointment of Joshua Blacher as Chief Business Officer

VANCOUVER , April 11, 2018 /CNW/ – InMed Pharmaceuticals Inc. (“InMed” or the “Company”) (TSX:IN; OTCQB: IMLFF), a biopharmaceutical company specializing in the research and development of novel, cannabinoid-based drug therapies, today announced the appointment of Joshua Blacher as Chief Business Officer.  In this capacity, Mr. Blacher will be focusing on raising the Company’s visibility in the broader capital markets community, especially in the United States , as well as executing strategic finance initiatives and business development.

InMed Pharmaceuticals Inc. (CNW Group/InMed Pharmaceuticals Inc.)

Mr. Blacher joins InMed with twenty years of leadership experience in senior positions in the healthcare and capital markets sectors in the United States.  Before joining InMed, Mr. Blacher served as Chief Financial Officer at Therapix Biosciences (TRPX) and Galmed Pharmaceuticals (GLMD), where he focused on strategic finance, business development, and managing relations with the investment community.  Previously, Mr. Blacher also held senior positions in licensing and investing at Teva Pharmaceuticals, portfolio management at Deutsche Asset Management and equity research at Morgan Stanley, as well as in mergers & acquisitions at Lehman Brothers.  Mr. Blacher holds an MBA in Finance from Columbia Business School .

Eric A. Adams , InMed’s President and CEO, commented, “Josh brings his many years of experience in successfully helping to build a larger vision for high-growth biopharmaceutical companies, executing investor-focused awareness, and putting together strategic collaborations.”  Mr. Adams continued, “Adding Josh’s unique skill set to our executive team is very timely to InMed, as we have now secured the capital and human talent to drive the Company into its next stage of strategic growth and execution of our focused business model.”

“InMed’s valuable platform technology and R&D pipeline uniquely situates the Company in the high-growth, cannabinoid-based biopharmaceutical industry,” commented Mr. Blacher.  “The Company is clearly positioned at the early stages of its growth trajectory and there exists a great opportunity to capitalize on its distinct business model and drive shareholder value.  I am very excited to join the InMed team and look forward to helping the Company accomplish its objectives.”

About InMed: 
InMed is a preclinical stage biopharmaceutical company specializing in the research and development of novel, cannabinoid-based prescription drug therapies utilizing novel drug delivery systems. InMed conducts research, discovery, preclinical, regulatory, manufacturing and commercial development activities for its product candidates. InMed’s proprietary bioinformatics platform, its biosynthesis manufacturing process and its drug development programs are the fundamental value drivers of the Company. For more information, visit www.inmedpharma.com.

Cautionary Note Regarding Forward-Looking Information:       
This news release contains “forward-looking information” and “forward-looking statements” (collectively, “forward-looking information”) within the meaning of applicable securities laws. Forward-looking information is based on management’s current expectations and beliefs and is subject to a number of risks and uncertainties that could cause actual results to differ materially from those described in the forward-looking statements. Forward-looking information in this news release includes statements about: Mr. Blacher serving as InMed’s Chief Business Officer; Mr. Blacher focusing on raising the Company’s visibility in the broader capital markets community, especially in the United States , as well as executing strategic finance initiatives and business development; driving InMed into its next stage of strategic growth; capitalizing on InMed’s distinct business model and driving shareholder value; and the expected fundamental value drivers of the Company.

With respect to the forward-looking information contained in this news release, InMed has made numerous assumptions regarding, among other things: Mr. Blacher’s continued availability; positive drug development results; demand for InMed’s products; and continued economic and market stability. While InMed considers these assumptions to be reasonable, these assumptions are inherently subject to significant business, economic, competitive, market and social uncertainties and contingencies.

Additionally, there are known and unknown risk factors which could cause InMed’s actual results, performance or achievements to be materially different from any future results, performance or achievements expressed or implied by the forward-looking information contained herein. Known risk factors include, among others: Mr. Blacher may become unwilling or unable to act as Chief Business Officer; InMed may alter its strategic focus; economic or market conditions may worsen; and InMed’s proprietary bioinformatics platform, biosynthesis manufacturing process and drug development programs may not become the fundamental value drivers of the Company.

A more complete discussion of the risks and uncertainties facing InMed is disclosed in InMed’s most recent Annual Information Form and other continuous disclosure filed with Canadian securities regulatory authorities on SEDAR at www.sedar.com. All forward-looking information herein is qualified in its entirety by this cautionary statement, and InMed disclaims any obligation to revise or update any such forward-looking information or to publicly announce the result of any revisions to any of the forward-looking information contained herein to reflect future results, events or developments, except as required by law.

NEITHER THE TORONTO STOCK EXCHANGE NOR ITS REGULATIONS SERVICES PROVIDER HAVE REVIEWED OR ACCEPT RESPONSIBILITY FOR THE ADEQUACY OR ACCURACY OF THIS RELEASE.

Cision
Cision

View original content with multimedia:http://www.prnewswire.com/news-releases/inmed-announces-appointment-of-joshua-blacher-as-chief-business-officer-300627543.html

SOURCE InMed Pharmaceuticals Inc.

The post InMed Announces Appointment of Joshua Blacher as Chief Business Officer appeared first on CannabisFN.

Why Micropropagation is the Future of Cannabis Cultivation

The cannabis industry is projected to exceed $50 billion by 2026, according to Cowen & Co., driven by the legalization of medical and adult-use cannabis throughout the United States. While most companies are focused on cultivation and retail sales, there are some companies focused on making the industry safer, better, and more efficient. The techniques pioneered by these companies are becoming increasingly necessary to help the industry scale to meet demand.

Segra International Corp. is a pioneer in micropropagation, also known as plant tissue culture, which is designed to help cultivators increase their yields, reduce harmful pathogens, and ultimately help scale production to meet growing medical and adult-use demand worldwide. The company plans to go public later in 2018.

Click here to receive Segra International updates prior to the company going public.

How Most Cannabis is Grown

You might think of seeds as the natural starting point for growing plants, but growing a plant from a seed takes a long time and each resulting plant is different.

Large-scale commercial cannabis cultivators prefer to use clones, or genetically identical plantlets, derived from mother plant cuttings or other methods. By cutting a healthy lower branch, placing it immediately into water, and transporting the clone into soil, these cultivators can grow genetically identical plants. The clones have a much shorter growing window than plants derived from seeds, while each plant has identical cannabinoid and terpene ratios.

The problem is that this approach is labor intensive and requires a lot of physical space to maintain mother plants. This space for mother plants and cloning could otherwise be used for production and generate revenue if not required for nursery operations. In addition, mother plants have a finite lifespan and are more susceptible to pathogens as a result of their long residence times. Any clones derived from a pathogen-carrying mother plant will have the same infections and carry those into the vegetative and flowering stages of production. All of this means that the current process is not efficient, safe, or scalable and could lead to complete crop (and strain) loss in the event of an uncontrollable pathogen outbreak – a cultivator’s worst nightmare.

Why Micropropagation?

Many traditional agricultural crops have faced these same issues, but they have managed to effectively scale using a tissue culture technique known as micropropagation.

Micropropagation is a method of plant propagation using extremely small pieces of plant tissue taken from a carefully chosen and prepared mother plant, and rapidly growing these under sterile laboratory conditions to produce new plants.

Most plantlets produced this way are sold at the rooting stage when the plantlet is ready to be acclimated the final growing environment. Commercial cannabis cultivators can purchase these plantlets and acclimate them to their unique growing environment before moving them into the main greenhouse. This process takes very little time compared to the time it takes to grow a plant from a seed or clone a plant from cuttings from a mother plant.

Gaining Traction Among LPs

Many licensed producers are embracing tissue culture techniques and micropropagation as a way to dramatically lower their costs, reduce the risk of pathogens, and ensure the best products for patients and consumers. In fact, LPs can effectively increase their productive square footage by five to 20 percent by eliminating the space that was used for mothering plants. They can also avoid pathogens without the use of pesticides, creating cleaner and safer products.

Segra International’s recent partnership with The Hydropothecary Corporation (TSX-V: THCX) is a perfect example of these benefits. Under the terms of the deal, Segra will provide its expertise and unique tissue culture techniques to help the licensed producer scale up its operations to meet market demand in Canada’s upcoming recreational market this summer. The partnership is expected to rapidly scale into millions of plantlets per year.

“Working with Segra will allow us to meet one of the biggest challenges as we meet the demand for cannabis products across Canada and beyond, balancing quality and quantity in our cannabis production,” said Hydropothecary CEO Sebastien St-Louis. “Thanks to Segra’s plant tissue culture technique, we will scale up our production process while maintaining the industry-leading quality standards that have made us so successful.”

Click here to receive Segra International updates prior to the company going public.

Looking Ahead

Segra International Corp. is targeting a major pain point for licensed producers and is developing micropropagation labs to deliver tens of millions of plantlets to LPs across Canada. The company plans to go public later in 2018.

Segra’s world-class management team includes Director of Tissue Culture, Dr. Sma Zobayed, a leading specialist in plant tissue culture with two patents related to the subject and over 50 published scientific papers; Chief Marketing Officer, Ian Davidson, who founded Davidson Organics, one of the largest cultivators in California; and, Chief Operations Officer, Ryan Tiberti, who has developed, built, and operated several multi-million dollar cannabis firms in the U.S.

Click here to receive Segra International updates prior to the company going public.

Disclaimer 

The above article is sponsored content. Emerging Growth LLC, which owns CannabisFN.com and CFN Media, has been hired to create awareness. Please follow the link below to view our full disclosure outlining our compensation: http://www.cannabisfn.com/legal-disclaimer/

The post Why Micropropagation is the Future of Cannabis Cultivation appeared first on CannabisFN.

Delta 9 Cannabis Inc. Signs Letter of Intent with Pharmasave

WINNIPEGApril 10, 2018 /CNW/ – DELTA 9 CANNABIS INC. (TSXV: NINE) (“Delta 9” or the “Company”) has entered into a non-binding letter of intent (the “Letter of Intent”) to become a preferred supplier of medical cannabis to Pharmasave.

Delta 9 Cannabis was the fourth company chosen as a Licensed Producer in Canada, and has now signed an LOI to become a Preferred Supplier of medical cannabis through the Pharmasave chain of member-owned pharmacies. (CNW Group/Delta 9 Cannabis Inc.)

Pharmasave is a member owned and governed cooperative of more than 650 independent community pharmacies across Canada. Pharmasave believes that pharmacists, as medication management experts, play an important role in helping to improve patient care. For more than a year, Pharmasave has been providing education and resources on medical cannabis to help Pharmasave pharmacists understand more about the current regulations and learn more about the possible uses, benefits and risks of medical cannabis. Pharmacists can provide advice on potential drug-to-drug interactions and the therapeutic value of treatment options to patients and allied health professionals to help them make educated and informed decisions about products and monitoring.

Following execution of the Letter of Intent, the two companies are jointly working to conclude definitive agreements for supply and distribution of Delta 9’s medical cannabis through Pharmasave pharmacists, pending changes to Canadian legislation that would allow such distribution.

Delta 9 CEO John Arbuthnot says the agreement is part of Delta 9’s ongoing commitment to supplying patients with the medical products they need in a timely and reliable manner.

“There has been a lot of discussion about the upcoming legalization of recreational cannabis, but we at Delta 9 remain committed to providing our medical cannabis patients with the products they require,” Arbuthnot said. “Pharmasave and its member stores provide the expertise and professionalism this industry needs to ensure patients are receiving the correct products, and good advice on how to use these products for their particular condition or symptoms.”

“We believe this agreement with Pharmasave is a critical part of professionalizing the medical cannabis industry, and we are dedicated to providing the best products and service possible to our patients.”

The parties are currently working on agreement terms to ensure compliance with the Access to Cannabis for Medical Purposes Regulations (Canada) and all other applicable laws and regulations.

About Delta 9 Cannabis Inc.
Delta 9’s wholly-owned subsidiary, Delta 9 Bio-Tech Inc., is a licensed producer of medical marijuana pursuant to the ACMPR and operates an 80,000 square foot production facility in Winnipeg, Manitoba, Canada. Delta 9’s shares trade on the TSX Venture Exchange under the symbol “NINE”.

Neither the TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in the policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release.

Disclaimer for Forward-Looking Information

Certain statements in this release are forward-looking statements, which reflect the expectations of management regarding the Company’s future business plans and other matters. Forward-looking statements consist of statements that are not purely historical, including any statements regarding beliefs, plans, expectations or intentions regarding the future. Forward looking statements in this news release include statements relating to: (i) the execution of definitive supply and distribution agreements between Pharmasave and Delta 9; and (ii) anticipated changes to cannabis legislation in Canada. Such statements are subject to risks and uncertainties that may cause actual results, performance or developments to differ materially from those contained in the statements, including that Delta 9’s currently contemplated expansion and development plans may cease or otherwise change, Delta 9’s production of cannabis may be lower than expected, Delta 9 may not obtain the required approvals from Health Canada, demand for Delta 9’s products may be lower than anticipated, Delta 9’s cost to produce its grow pods may be higher than expected and all other risk factors set forth in the filing statement of Delta 9 dated October 25, 2017 which has been filed on SEDAR. No assurance can be given that any of the events anticipated by the forward-looking statements will occur or, if they do occur, what benefits the Company will obtain from them. Readers are urged to consider these factors carefully in evaluating the forward-looking statements contained in this news release and are cautioned not to place undue reliance on such forward-looking statements, which are qualified in their entirety by these cautionary statements. These forward-looking statements are made as of the date hereof and the Company disclaims any intent or obligation to update publicly any forward-looking statements, whether as a result of new information, future events or results or otherwise, except as required by applicable securities laws.

SOURCE Delta 9 Cannabis Inc.

View original content with multimedia: http://www.newswire.ca/en/releases/archive/April2018/10/c2941.html

Gary Symons, Director of Communications, communications@delta9.ca, 250.300.9352Copyright CNW Group 2018

 

Source: Canada Newswire (April 10, 2018 – 5:30 AM EDT)

The post Delta 9 Cannabis Inc. Signs Letter of Intent with Pharmasave appeared first on CannabisFN.

India Globalization Capital Files Patent for Hyalolex Formulation

BETHESDA, Md.–(BUSINESS WIRE)–

India Globalization Capital, Inc. (NYSE Amex:IGC) today announced that it has filed a method and composition patent with the U.S.P.T.O. for the formulation of Hyalolex (IGC-507), which helps address some symptoms of Alzheimer’s disease including the buildup of plaques and tangles, anxiety, aggression and sleep disorders among others.

This patent filing enables IGC to pursue the commercialization of this formulation in U.S. states where medical cannabis is legal, as well as in selected European countries. As previously announced, IGC will start its marketing activities in Puerto Rico with subsequent initiatives in ten key markets in the U.S.

In addition, the new patent filing allows the Company to disclose its specific method of manufacturing Hyalolex and specific active ingredients to appropriate health departments, processors, growers, doctors, caregivers, patients and dispensaries, which will be integral to the acceleration of IGC’s marketing efforts. According to CEO Ram Mukunda, the Company will also incorporate the formulation and active ingredients in its website and through its presentations. “As this evolves our Company will evidence its goal of becoming a market leader in specific areas where we will have a head-start, such as Alzheimer’s,” he said.

The Company is launching Hyalolex in Puerto Rico, as previously reported, in part because the Latino population is especially susceptible to Alzheimer’s disease with a much higher likelihood of contracting the disease. In total, there are over 5.5 million adults with Alzheimer’s in the U.S. and over 44 million worldwide. After launching marketing initiatives for Hyalolex in Puerto Rico, IGC will commence marketing and licensing arrangements in states including Maryland, Washington, D.C. and California.

By the end of the year, Mukunda says he expects IGC to have its Alzheimer’s product in 10 U.S. states. “In the process, we will build a distribution and brand presence that we can leverage for our other products and bring relief to those afflicted with this difficult diagnosis,” he said.

About IGC

IGC has two lines of business, (i) a legacy commodity trading, and infrastructure business, and (ii) a cannabis based complimentary medicines business that has developed a lead product for treating Alzheimer’s patients. IGC recently announced that it is working on using blockchain to address issues specific to the cannabis industry including transactional difficulties, product labeling, product identification assurance (PIA), and product origin assurance (POA). IGC is based in Maryland, USA.
For more information please visit www.igcinc.us
Follow us on Twitter @IGCIR and Facebook.com/IGCIR/

Forward-looking Statements

Please see forward looking statements as discussed in detail in IGC’s Form 10K for fiscal year ended March 31, 2017, and in other reports filed with the U.S. Securities and Exchange Commission.

The post India Globalization Capital Files Patent for Hyalolex Formulation appeared first on CannabisFN.

High Hampton Retains Marc J. Ross as U.S. Cannabis Legal Counsel

ORONTOApril 10, 2018 /CNW/ – High Hampton Holdings Corp. (CSE: HC)(FSE: 0HCN) (“High Hampton” or the “Company“) today announced that it has retained Marc J. Ross, Esq., of Sichenzia Ross Ference Kesner LLP, as the Company’s U.S. Cannabis Legal Counsel to advise and consult on all cannabis-related legal matters as applicable to the Company’s business model, strategy and possible future acquisitions.

David E. Argudo, CEO of High Hampton, commented:

“We are pleased to be able to attract a distinguished legal professional such as Marc to our team. His relationships and experience at the federal level coupled with his in-depth knowledge of the U.S. Securities and Exchange Commission and U.S. capital markets make Marc an asset to High Hampton. I welcome him and his firm as we navigate through the developing federal legal framework of our industry and look forward to working closely with Marc in continuing to build and grow High Hampton and consolidate the California cannabis market.”

Marc J. Ross, Esq., adds:

“I am excited to be joining High Hampton, as they seek to become a major player in the cannabis industry. In building their business strategy around market consolidation, their team seeks to anticipate cannabis sector trends, and I look forward to contributing to their success.”

About Marc J. Ross

Marc J. Ross is a founding partner of Sichenzia Ross Ference Kesner LLP, formerly known as Sichenzia Ross Friedman Ference LLP, a firm he started in 1998 which specializes in corporate, securities, litigation and regulatory matters.

In the securities and corporate area, Mr. Ross advises companies with their 1934 Act reporting requirements as well as their NASDAQ, AMEX and NYSE and other exchange listing and compliance matters.  In addition, Mr. Ross assists companies going public, whether through a reverse merger (RTO), initial public offering (IPO), or company offering (DPO).  He also advises clients on investment and capital raising transactions, including private investments in public equities (PIPEs), initial public offerings (IPOs), registered direct offerings (RDs), and shelf offerings.

In the litigation and regulatory area, Mr. Ross represents clients in commercial/securities matters from arbitrations before FINRA, the AAA, and JAMS, to court cases nationwide.  Mr. Ross also counsels clients in civil regulatory and possible criminal investigations before self-regulatory organizations, state agencies, or federal agencies, and he regularly appears before the SEC, FINRA, and state securities agencies in connections with their investigations.

Mr. Ross also specializes in advising marijuana and marijuana-related companies.  In particular, he is very knowledgeable in, and often speaks on, the legal issues associated with marijuana and marijuana-related businesses, including the interplay between state laws which legalize recreational and/or medical marijuana uses, and federal laws which bar such uses.

Mr. Ross teaches the first law school course on marijuana at Hofstra University School of Law, titled Business and Law of Marijuana.  In his course, Mr. Ross introduces students to the rapidly-developing legal questions encountered in the operation of marijuana-related businesses. The course uses a fictional business, Cannabis Inc., to explore (1) the interplay between state laws legalizing recreational and/or medical marijuana uses and the Federal Controlled Substances Act; (2) enforcement and application of other regulatory regimes governing the operation of marijuana-related businesses, such as banking and securities laws; and (3) the ethical considerations for an attorney advising a client engaged in a marijuana-related business.

About High Hampton Holdings

High Hampton Holdings is a cannabis sector investment company focused on opportunities in California. The Company’s wholly owned subsidiary, CoachellaGro Corp., is a California corporation focused on the development of a 10.8-acre property situated in the proposed cannabis industrial park located in Coachella, California. CoachellaGro is in the application process for a conditional use permit for development of a full-service production facility in order to serve third party state licensed medical marijuana operators. The City of Coachella has been progressive in setting up city ordinance that sets aside over 90 acres within which will be a legal framework for the cultivation, production, extraction and transportation of cannabis. The complex is intended to contain all the necessary; security, infrastructure, equipment, labour and skilled management, supplies and ancillary services for a closed loop production process flow.

Social Media

Facebook: facebook.com/highhampton
Twitter: twitter.com/highhamptonHC
LinkedIn: linkedin.com/HighHampton

Stock Exchanges

High Hampton trades in Canada, ticker symbol HC on the CSE, and in Europe, ticker symbol 0HCN on the FSE. Neither the CSE, nor the FSE has approved nor disapproved the contents of this press release. Neither the CSE, nor the FSE accepts responsibility for the adequacy or accuracy of this release.

Marijuana Industry Involvement

Canadian listings (CSE) will remain in good standing as long as they provide the disclosure that is required by regulators and complying with applicable licensing requirements and the regulatory framework enacted by the applicable state in which they operate. Marijuana is legal in certain states however marijuana remains illegal under US federal law and the approach to enforcement of US federal law against marijuana is subject to change. Shareholders and investors need to be aware that adverse enforcement actions could affect their investments and that High Hampton’s ability to access private and public capital could be affected and or could not be available to support continuing operations.

On behalf of the Board of Directors

High Hampton Holdings Corp.

Certain statements contained in this press release constitute forward-looking information. These statements relate to future events or future performance. The use of any of the words “could”, “intend”, “expect”, “believe”, “will”, “projected”, “estimated” and similar expressions and statements relating to matters that are not historical facts are intended to identify forward-looking information and are based on the Company’s current belief or assumptions as to the outcome and timing of such future events. Actual future results may differ materially. In particular, this release contains forward-looking information relating to the intention of the parties to complete the Acquisition and certain ancillary transactions contemplated thereby. These transactions are subject to a number of material risks, and there is no assurance that they will be completed on the terms or within the timeframes currently contemplated, or at all. The forward-looking information contained in this press release is made as of the date hereof and the Company is not obligated to update or revise any forward-looking information, whether as a result of new information, future events or otherwise, except as required by applicable securities laws. Because of the risks, uncertainties and assumptions contained herein, investors should not place undue reliance on forward-looking information. The foregoing statements expressly qualify any forward-looking information contained herein.

All monetary references herein refer to Canadian dollars unless otherwise specified.

SOURCE High Hampton Holdings Corp.

View original content: http://www.newswire.ca/en/releases/archive/April2018/10/c4977.html

8 Wellington St. E. Mezzanine Level | Toronto, On | M5E 1C5 | www.HighHampton.com; David E. Argudo, Chief Executive Officer, Email: david@highhampton.com, Or Christian Scovenna, Director & VP Corporate Finance, Email: christian@HighHampton.com, Phone: 416.453.4708Copyright CNW Group 2018

 

Source: Canada Newswire (April 10, 2018 – 3:15 AM EDT)

The post High Hampton Retains Marc J. Ross as U.S. Cannabis Legal Counsel appeared first on CannabisFN.

NanoSphere Health Sciences Achieves Landmark Patent

Researchers might know that active pharmaceutical ingredients produce a certain result in cells, but they often face difficulty delivering those APIs to target areas within the body. Many of the most promising companies in the biotech and pharmaceutical spaces are focused on developing drug delivery technologies designed to bring precise doses of APIs to highly specific targets without being degraded by the liver, digestive system or other parts of the body.

NanoSphere Health Sciences Inc. (CSE: NSHS) (OTC: NSHSF) recently announced that the United States Patent and Trademark Office granted Patent No. 9,925,149 covering the core technology behind the production of its NanoSphere Delivery System™, which paves the way for commercialization of its breakthrough delivery technology. Investors may want to take a closer look at the stock given these catalysts.

NanoSphere Delivery System

NanoSphere Health Sciences’ NanoSphere Delivery System™ is one of the most important advancements for the non-invasive delivery of biological agents in over 25 years. By nanoencapsulating a broad range of bioactive compounds in a protective, lipid membrane, the delivery platform transports them rapidly and effectively into the bloodstream and cells, while  also making the active ingredients safer and more bioavailable by delivering precise doses to target sites.

The cannabis industry may be legal across much of North America, but physicians and patients have struggled to accurately prescribe the drug even if they know it’s safe and efficacious. For example, researchers have found that the bioavailability of cannabinoids differs greatly between individuals and delivery methods. The company’s NanoSphere Delivery System™ can help bypass first-pass metabolism and enhance and stabilize the bioavailability of cannabinoids.

In addition to cannabis, the NanoSphere Delivery System™ can be applied to many different hard-to-absorb nutrients, such as fat-soluble vitamins, fatty acids, minerals, botanical extracts, and phytochemicals. The technology could help increase bioavailability of these agents compared to traditional methods without the need to swallow capsules or take tinctures. These benefits could be enormous in the multi-billion dollar nutraceutical industry.

Building an IP Portfolio

NanoSphere Health Sciences’ new patent broadly covers the formation and manufacturing of lipid, structural nanoparticles, which is the NanoSphere Delivery System™, for the delivery of cannabinoids, pharmaceuticals, nutraceuticals, cosmeceuticals, and other biological agents. In particular, the patent extends to its 16 forms of lipid nanoparticle structures, which can be applied across healthcare sectors for vastly improved delivery of active pharmaceutical ingredients.

“The granting of the patent for the NanoSphere Delivery System™ secures our position as a leader in advanced nanoparticle delivery,” said NanoSphere Health Sciences CEO Robert Sutton in the press release announcing the new patent. “Major industries have the potential to be reshaped and reimagined by our next-generation technology.”

With the new patent, NanoSphere Health Sciences will have long-term market exclusivity over the delivery platform. The company plans to license the patented NanoSphere Delivery System™ and its proprietary manufacturing process to select companies in its target industries to maximize commercialization. The patent also enables the company to develop its own product lines, including Evolve Formulas’ transdermal, intranasal, and intraoral cannabis applications.

Looking Ahead

NanoSphere Health Sciences Inc. (CSE: NSHS) (OTC: NSHSF) represents a compelling investment opportunity in the drug delivery space. With its new patent in place, the company is well-positioned to commercialize its breakthrough technology in both the cannabis industry and the wider nutraceutical and pharmaceutical industries. Keep an eye NanoSphere as it pursues opportunities in these potentially lucrative markets.

For more information, visit the company’s website at www.nanospherehealth.com.

Disclaimer

The above article is sponsored content. Emerging Growth LLC, which owns CannabisFN.com and CFN Media, has been hired to create awareness. Please follow the link below to view our full disclosure outlining our compensation: http://www.cannabisfn.com/legal-disclaimer/

 

 

The post NanoSphere Health Sciences Achieves Landmark Patent appeared first on CannabisFN.

Therapix Biosciences Announces Topline Results of Phase IIa Study at Yale University for Tourette Syndrome Program

– Study meets its primary endpoint –

TEL AVIV, IsraelApril 9, 2018 Therapix Biosciences Ltd. (NASDAQ: TRPX) (“Therapix” or “the Company”), a biopharmaceutical company focused on discovering, developing, and commercializing novel therapeutics from its proprietary cannabinoid product platform THX-110, announced today topline results from its investigator-initiated Phase IIa study at Yale University, suggesting that THX-110 [which is a combination of dronabinol (∆-9-tetrahydracannabinol) and palmitoylethanolamide (PEA)] significantly  improved symptoms over time in adult Subjects with Tourette syndrome.

“The successful completion of this study is a key milestone in our clinical development plan of our proprietary drug candidate THX-110 for the treatment of Tourette syndrome for which current available treatments are frequently inadequate or unsafe,” said Adi Zuloff-Shani, Ph.D, Chief Technology Officer at Therapix. “Moreover, these results are of particular interest as the pharmacology of THX-110 appears to be distinct from existing medications for TS and may offer a unique option for treating these patients. This study was designed primarily to confirm safety, tolerability and feasibility in this challenging patient population and is encouraging that we obtained positive data that suggests that the combination of dronabinol (∆-9-tetrahydracannabinol) and palmitoylethanolamide (PEA) (THX-110) should be pursued as a treatment for TS patients,” continued Dr. Zuloff-Shani. “Based on these study results, we intend to initiate a randomized, double-blind, placebo controlled study to evaluate the safety, tolerability and efficacy of daily oral THX-110 in treating adults with Tourette syndrome.”

The study was a single-arm, open-label trial, in which each subject both received one daily treatment of the drug via oral administration and was followed-up for a period of 12 weeks. Sixteen subjects participated in the study and received THX-110 at the Yale University Child Study Center at Yale UniversityUSA. The primary endpoint of the study was to assess the performance of THX-110 in the treatment of adult patients suffering from symptoms of Tourette syndrome, as measured by the Yale Global Tic Severity Scale Total Tic Score (YGTSS-TTS), the gold-standard and customary index for assessing symptom severity. Treatment was given in a dose titration regimen with a maximum dose of THX-110 consisting of 10mg Dronabinol and 800mg PEA.

The study was investigator-initiated and led by Michael H. Bloch, M.D., Associate Professor at the Yale University Child Study Center, and James F. Leckman, M.D., Ph.D., of the Neison Harris Professor in the Child Study Center and Professor of Pediatrics Child Psychiatry at Yale University.

The study showed that these 16 subjects with medication-refractory TS had a reduction of tic symptoms (paired t-test: YGTSS-TTS mean difference (mean +/- SD) =7.9+/-8.4, t= 3.7, df=15, p=0.002) from baseline (YGTSS-TTS: 38.4 +/- 8.3) to endpoint (YGTSS-TTS: 30.5 +/- 10.9). This resulted in an average tic reduction of 21% across the entire sample.

Six of the 16 medication-refractory TS subjects experienced a response to treatment as defined by a reduction in YGTSS-TTS of greater than 25%. Improvement over time with treatment was also observed when generalized linear models were used to analyze repeated measures data on the YGTSS-TTS. THX-110 demonstrated no significant effects on comorbidity. The medication was generally well-tolerated by subjects with only two subjects stopping treatment early (one due to sedation and another due to lack of improvement in tic symptoms). Twelve of the 16 subjects elected to continue into a 24-week extension phase of the trial, which is nearing completion.

“In general, this study enrolled 16 adults, most of which had severe, refractory Tourette syndrome that had not responded to previous evidence-based treatment (e.g. antipsychotic medications, alpha-2 agonists, behavioral therapy) and multiple investigational compounds (e.g. topiramate, VMAT-inhibitors, repetitive transcranial magnetic stimulation, deep brain stimulation). A subset of these subjects experienced improvement in tic symptoms during the course of the study. The overall improvement of tics in this sample of severe, adult TS is quite encouraging and further placebo-controlled trials are needed in an attempt to demonstrate efficacy,” said Dr. Michael Bloch, M.D., principal investigator of the study.

“We believe that the efficacy demonstrated in this study further reinforce the potential role of cannabinoids in the field of CNS and movement disorders and suggests that Therapix Biosciences may have a proprietary cannabinoid product candidate in the treatment of Tourette syndrome,” stated Dr. Ascher Shmulewitz,  M.D., Ph.D, Chairman and interim CEO of Therapix said. “These data are a catalyst for the acceleration of Therapix’s Entourage Effect research interests.”

Complete results from this study will be presented at the 2018 European Society for the Study of Tourette syndrome meeting in Copenhagen, Denmark.

About Therapix Biosciences

Therapix Biosciences Ltd. is a specialty clinical-stage pharmaceutical company led by an experienced team of Senior Executives and Scientists. Our focus is creating and enhancing a portfolio of technologies and assets based on cannabinoid pharmaceuticals. With this focus, the company is currently engaged in the following drug development programs based on repurposing an FDA-approved synthetic cannabinoid (Dronabinol): THX-110 for the treatment of Tourette syndrome (TS), for the treatment of Obstructive Sleep Apnea (OSA), and for the treatment of Pain; THX-130 for the treatment of Mild Cognitive Impairment (MCI) and Traumatic Brain Injury (TBI); and THX-150 for the treatment of infectious diseases. Please visit our website for more information at www.therapixbio.com

Forward-looking statements

This press release contains forward-looking statements within the meaning of the “safe harbor” provisions of the Private Securities Litigation Reform Act of 1995 and other Federal securities laws. Because such statements deal with future events and are based on Therapix’s current expectations, they are subject to various risks and uncertainties and actual results, performance or achievements of Therapix could differ materially from those described in or implied by the statements in this press release. For example, forward-looking statements include statements regarding the Company’s plans with respect to its clinical trials and its intent to report material developments and information regarding such trials. In addition, historic results of scientific research and clinical and preclinical trials do not guarantee that the conclusions of future research or trials will suggest identical or even similar conclusions. The forward-looking statements contained or implied in this press release are subject to other risks and uncertainties, including those discussed under the heading “Risk Factors” in Therapix Biosciences Ltd.’s Annual Report on Form 20-F filed with the Securities and Exchange Commission (SEC) on May 1, 2017 and in subsequent filings with the SEC. Except as otherwise required by law, Therapix disclaims any intention or obligation to update or revise any forward-looking statements, which speak only as of the date they were made, whether as a result of new information, future events or circumstances or otherwise.

Investor Contact
Oz Adler,
VP Finance
oz@therapixbio.com

Media Contact
Sydney Masters
Sydney@MastersMallory.com
M: 917-584-8385
P: 212-987-6804

 

SOURCE Therapix Biosciences Ltd.

The post Therapix Biosciences Announces Topline Results of Phase IIa Study at Yale University for Tourette Syndrome Program appeared first on CannabisFN.

Plus Products Concludes $6M Series B Financing

Branded Cannabis Products Company Expands To Satisfy Demand

PALO ALTO, Calif., April 09, 2018 (GLOBE NEWSWIRE) — Plus Products, the cannabis infused products manufacturer, announced today that it has closed approximately $6M in Series B financing to expand its operations and satisfy California’s growing demand for cannabis infused edibles. The financing was led by Serruya Private Equity Partners (SPE) and Navy Capital Green Fund LP. Proceeds will be used to fund rapid production capacity expansion, factory automation, working capital, and new product development.

“We are extremely proud of the products PLUSTM has brought to market,” says Jake Heimark, CEO and cofounder. “We’ve quickly grown into one of the leading edible brands in California. With the proceeds of this round, we will continue to further our mission: to make cannabis safe and approachable for all types of consumers.”

Plus Gummies
Plus Products - Gummies
At PLUS™ we believe great products begin with great sourcing. Our process begins with the highest quality extracts. We pair these with carefully selected ingredients and make every batch from scratch. The final result is consistent, fast acting, great tasting edibles.

Plus Products received the eighth temporary manufacturing license in California and was one of the first brands to bring fully compliant products to the legal market. All products under the PLUSTM brand are produced in the company’s dedicated food-safe cannabis manufacturing facility in Adelanto, California. The 12,000 square foot facility was outfitted for scalable food production with funds raised in 2017’s Series A round, led by The Green Organic Fund and Verde Mountain Fund.

Edibles are big business in California. According to BDS Analytics, Edibles made up 18% of marijuana retail sales in February 2018 across licensed retailers in California and PLUSTM ranked in the top ten of edible brands by retail dollar sales. With the introduction of adult use recreational sales on January 1st, 2018, it is expected that edible sales will continue to grow rapidly as they did in Colorado and Washington.

“2018 is an historic year for California’s cannabis industry with the official launch of legalized adult use,” said John T. Kaden, Manager and Chief Investment Officer of the Navy Capital Green Fund. “PLUSTM is establishing a leading position in California and has assembled the right management team to execute and succeed in this complex regulated environment.”

The team continues to focus on producing branded cannabis products that are compliant with state laws. In addition to its established lines, Plus Products has already begun launching limited edition products including Valentine’s day themed Rose & Vanilla gummies, which were available at select locations of the company’s 200+ dispensaries and delivery service partners.

About Plus Products
Plus Products is a branded cannabis products manufacturer headquartered in Palo Alto, California. The company has introduced fast-acting edibles positioned for a healthy and active lifestyle audience seeking a premium cannabis experience. All products are hand-crafted with high quality ingredients without the gluten and calories found in competing edible products.

About Serruya Private Equity Partners (SPE)
Serruya Private Equity Inc. (SPE) is a Toronto-area based, family managed group that invests capital in a broad range of asset classes, with an emphasis on retail and real estate. SPE’s principals have a legacy of developing national and International brands, and its affiliates include global brands such as Yogen Fruz, Cold Stone Creamery, Pinkberry and Swensens, with over one billion dollars of worldwide system revenue.

About Navy Capital
Navy Capital is a New York City-based investment manager currently deploying its Navy Capital Green Fund LP, which focuses on strategic, long-term investments in legal cannabis and cannabis-related industries.

This press release does not constitute an offer for sale in the United States. The offered Shares have not been registered under the United States Securities Act of 1933, as amended, and may not be offered or sold within the United States absent U.S. registration or an applicable exemption from U.S. registration requirements.

MEDIA CONTACT:
Heidi Groshelle
Ingrid Marketing
Tel  +1 415.307.1380
heidi@ingridmarketing.com
@heidigro

PLUS CONTACT:
hi@plusproducts.com

The post Plus Products Concludes $6M Series B Financing appeared first on CannabisFN.

RavenQuest Common Shares Listed on OTC now DTC Eligible

VANCOUVER, British Columbia, April 09, 2018 (GLOBE NEWSWIRE) — RavenQuest BioMed Inc. (the “Company” or “RavenQuest”) – (CSE:RQB) (OTCQB:RVVQF) (Frankfurt:1IT) today announced that it has secured DTC Eligibility for its common shares listed on the OTC market in the United States.

About the Depository Trust Company

The Depository Trust Company (DTC) is a subsidiary of the Depository Trust & Clearing Corporation DTCC and manages the electronic clearing and settlement of publicly traded companies. Securities that are eligible to be electronically cleared and settled through the DTC are considered “DTC eligible.” This electronic method of clearing securities speeds up the receipt of stock and cash, and thus accelerates the settlement process for investors.

About RavenQuest BioMed Inc.

RavenQuest BioMed Inc. is a diversified publicly traded cannabis company with divisions focused upon cannabis production, management services & consulting and specialized research & development.

On Behalf of the Board of Directors of
RAVENQUEST BIOMED INC.

“George Robinson”
Chief Executive Officer

For further information, please contact:
Mathieu McDonald, Corporate Communications – 604-484-1230

Neither Canadian Stock Exchange nor its Regulation Services Provider (as that term is defined in the policies of the Canadian Stock Exchange) accepts responsibility for the adequacy or accuracy of this press release, which has been prepared by management.

Primary Logo

 

Source: GlobeNewswire (April 9, 2018 – 6:00 AM EDT)

The post RavenQuest Common Shares Listed on OTC now DTC Eligible appeared first on CannabisFN.

Hiku’s licensed cannabis producer (DOJA) receives cannabis sales license from Health Canada

TORONTOApril 9, 2018 /CNW/ – Hiku Brands Company Ltd. (“Hiku” or the “Company“) (CSE: HIKU), Canada’s first vertically-integrated cannabis brand house, is pleased to announce its wholly owned subsidiary DOJA Cannabis Ltd. (“DOJA“), a licensed cannabis producer under the Access to Cannabis for Medical Purposes Regulations (the “ACMPR“), received an amendment to its license from Health Canada to include the sale of dried cannabis, cannabis plants and seeds, effective April 6, 2018.

Hiku Brands Company Ltd. (CNW Group/Hiku Brands Company Ltd.)

Receiving our license to sell is the crowning milestone in our licensing journey that started in 2013. Becoming only the 28th independent company in Canada with a cannabis sales license under the ACMPR gives Hiku the distinct advantage of being able to showcase and establish the DOJA brand in advance of legal adult-use and retail cannabis sales,” said Alan Gertner, CEO of Hiku.

With over $27 million of available cash and cash equivalents, Hiku is well capitalized to complete its next phase of cannabis production capacity growth. The build-out of Hiku’s second site facility, the “FUTURE LAB”, is well underway and expected to be completed in the summer of 2018, expanding Hiku’s annual production capacity to over 5,000 kg of dried cannabis flower ahead of Canada’s legal adult-use cannabis market.

About Hiku

Hiku is focused on building a portfolio of iconic, engaging cannabis brands, unsurpassed retail experiences and handcrafted cannabis production. With a national retail footprint led by Tokyo Smoke, craft cannabis production through DOJA‘s ACMPR licensed grow, and Van der Pop‘s female-focused educational platforms, Hiku houses an industry-leading portfolio that sets the bar for cannabis brands in Canada.

Hiku’s wholly-owned subsidiary, DOJA, is federally licensed to cultivate and sell cannabis pursuant to the ACMPR, owning two production facilities in the heart of British Columbia’s Okanagan Valley. Hiku operates a network of retail stores selling coffee, clothing and curated accessories, across British Columbia, Alberta and Ontario.

Regarding Forward-Looking Information

This news release contains statements that constitute “forward-looking statements”. Such forward-looking statements involve known and unknown risks, uncertainties and other factors that may cause Hiku’s actual results, performance or achievements, or developments in the industry to differ materially from the anticipated results, performance or achievements expressed or implied by such forward-looking statements. Forward-looking statements are statements that are not historical facts and are generally, but not always, identified by the words “expects,” “plans”, “anticipates”, “believes”, “intends”, “estimates”, “projects”, “potential” and similar expressions, or that events or conditions “will”, “would”, “may”, “could” or “should” occur.

Forward-looking statements in this document include statements regarding the anticipated completion date and production capacity of the Future Lab. By their nature, forward-looking statements are based on the opinions and estimates of management at the date the information is made, and is subject to a variety of risks and uncertainties and other factors that could cause actual events or results to differ materially from those projected in the forward-looking information. Hiku is not under any obligation, and expressly disclaims any intention or obligation, to update or revise any forward-looking information, whether as a result of new information, future events or otherwise, except as expressly required by applicable law.

The Canadian Securities Exchange has not approved nor disapproved the contents of this news release.

SOURCE Hiku Brands Company Ltd.

View original content with multimedia: http://www.newswire.ca/en/releases/archive/April2018/09/c3100.html

Abigail Van Den Broek, abby@abigailv.ca, 416-799-8510 or visit HIKU’s website at www.hiku.com.Copyright CNW Group 2018

The post Hiku’s licensed cannabis producer (DOJA) receives cannabis sales license from Health Canada appeared first on CannabisFN.

Segra Appoints World-Renowned Cannabis Breeding Expert David Watson to Advisory Board

VANCOUVERApril 5, 2018 /CNW/ – Segra International Corp. (“Segra”) is pleased to announce the appointment of David Watson to its advisory board.

Mr. Watson is one of the world’s top cannabis breeding experts and is credited by many with assembling the world’s most comprehensive cannabis seed library. He is also responsible for securing protection (breeders’ rights) for 29 cultivars under the International Union for the Protection of New Varieties of Plants. Since 1970, Mr. Watson has traveled extensively to cannabis-producing countries, looking for seeds of unusual varieties, and in 1975, he established Sacred Seeds, the world’s first cannabis seed company, in California. In 1986, he began Cultivator’s Choice, Amsterdam’s first cannabis seed company, breeding and introducing many foundation sinsemilla varieties that are still grown today. In 1992, Mr. Watson established HortaPharm BV, the world’s first established medical cannabis corporation, and in 1993, he cofounded the International Hemp Association. Working under license from the Dutch Ministry of Health, HortaPharm established facilities used to breed medical cultivars and conduct cannabis research and development. Mr. Watson formulated HortaPharm’s research goals and created the team led by Dr. Etienne de Meijer, which was the first to use silver thiosulfate as a breeding method to “self” cannabis plants and create single cannabinoid cultivars. In 1998, HortaPharm supplied varieties, along with organic cultivation and integrated pest management expertise, to GW Pharmaceuticals in the United Kingdom and assisted in selecting the cultivars used to produce Sativex® and other GW varieties. Mr. Watson co-authored Hemp Diseases and Pests (2000) with John McPartland and Robert Clarke, and he contributed to Franjo Grotenhermen’s Cannabis and Cannabinoids and Mahmoud ElSohly’s Marijuana and Cannabinoids, as well as a number of publications.

“Segra is extremely excited to have someone with David’s knowledge, credibility, and expertise on the advisory board,” said Todd McMurray, President/CEO. “This appointment is a monumental step forward in developing our worldwide plans to offer the best products for our cannabis micropropagation clients.”

About Segra

Segra is an agricultural life sciences company that specializes in cannabis plant micropropagation. The company is developing industrial-scale cannabis micropropagation laboratories to produce healthy, robust plantlets for licensed cannabis producers globally. Segra has assembled a world-class team of specialists in the areas of plant tissue culture, agronomy, molecular genetics, regulatory compliance, and corporate finance. The micropropagation team is led by Dr. Sma Zobayed, Segra’s Director of Micropropagation. Dr. Zobayed is a world-renowned micropropagation specialist who has successfully propagated over 500 species of plants, including cannabis. He has successfully developed a protocol for true-to-type cannabis micropropagation (including 4–7 x multiplication of plant stock over a 30-day period). Using this technology, Segra will help its clients improve product quality, expand operations, decrease liabilities associated with pests and diseases, and increase profits.

On behalf of the Board of Directors,

Todd McMurray, President/CEO

SEGRA INTERNATIONAL CORP.

This news release includes statements containing certain “forward-looking information” within the meaning of applicable securities law (“forward-looking statements”). Forward-looking statements are frequently characterized by words such as “plan”, “continue”, “expect”, “project”, “intend”, “believe”, “anticipate”, “estimate”, “may”, “will”, “potential”, “proposed” and other similar words, or statements that certain events or conditions “may” or “will” occur. These statements are only predictions. Various assumptions were used in drawing the conclusions or making the projections contained in the forward-looking statements throughout this news release. Forward-looking statements are based on the opinions and estimates of management at the date the statements are made, and are subject to a variety of risks and uncertainties and other factors that could cause actual events or results to differ materially from those projected in the forward-looking statements. The Company is under no obligation, and expressly disclaims any intention or obligation, to update or revise any forward-looking statements, whether as a result of new information, future events or otherwise, except as expressly required by applicable law.

SOURCE Segra International Corp.

For further information: Kevin Mehr, Phone: 604.284.3204, Email: kevin.m@segra-intl.com

The post Segra Appoints World-Renowned Cannabis Breeding Expert David Watson to Advisory Board appeared first on CannabisFN.

Future Farm Provides Rhode Island Update and Announces Speaking Engagement at Thought Leadership in the Dominican Republic

Vancouver, British Columbia , April 05, 2018 (GLOBE NEWSWIRE) —

Future Farm Technologies Inc. (the “Company” or “Future Farm”) (CSE: FFT) (OTCQX: FFRMF) is pleased to announce that it has completed the preliminary demolition of the interior of its Providence, Rhode Island building, which allows for the build-out of a cultivation facility to commence in earnest. The building is located in a M-1 zone, which legally permits the cultivation of cannabis by right. As previously announced, the Company intends to lease this property to a local, licensed cultivator who will use the property as a licensed medical marijuana cultivation space, providing wholesale cannabis to Rhode Island’s state-sanctioned dispensaries. Future Farm has already received a Letter of Intent to lease the property from a provisionally licensed cultivator and lease negotiations are currently underway.

During Phase I of the demolition, Future Farm’s Lessee began accepting and reviewing proposals for permit-ready sets of plans to lead the way to the next phases of development in the project. The Lessee has since engaged Creative Environment Corp. (a subsidiary of Theilsch Engineering, Inc.) and ZDS, Inc. to begin the architecture/engineering facility design phase. It is anticipated that Phase II of the build-out will be completed sometime in mid to late April.

“CEC and ZDS are two firms leading the industry in cannabis cultivation facility design,” says Derek Ross. “This is an amazing opportunity to work with two of the most accredited firms in the space. Their vast knowledge and experience has made the facility design process fast and efficient.”

Rhode Island’s governor recently introduced a budget proposal, which would dramatically expand Rhode Island’s medical marijuana program, most notably increasing the number of licensed compassion centers from three to 15. The governor also wants to add “acute pain” to the list of qualifying medical conditions, thereby making more people eligible for temporary medical marijuana cards after things such as dental work, sprained ankles and broken bones. “The combination of changes is projected to result in some $5.1 million in additional revenue to the state next year.”

Future Farm is also pleased to announce its participation in a seminar taking place on April 6th at the JW Marriott hotel in Santo Domingo, Dominican Republic. CannaEduca and Clinica Verde are co-sponsoring the event entitled “Legal, Social and Economic Aspects of Medicinal Cannabis: The Case of Puerto Rico.” For more information, see www.cannaeduca.com.

Future Farm adviser and strategic partner Derek Ross will be acting as panelist and featured speaker facilitating the discussion surrounding regulation and legislation of medical marijuana in the United States. This seminar will introduce the proven model in Puerto Rico to serve as a catalyst in the, as yet, untapped medical marijuana industry in the Dominican Republic. Officials and staff from the Ministries of Agriculture and Health are expected to be in attendance.

The Company also announces a correction to the previously announced finder’s fee payable to Atlas Capital Advisors, LLC with respect to Future Farm’s purchase of a convertible note from the company which holds a provisional certificate of registration to operate a registered marijuana dispensary in Attleboro, Massachusetts. As consideration for Atlas Capital’s services Future Farm agreed to pay $225,000 USD.

For further information, contact William Gildea, Director, at (888) 387-3761.

On behalf of the Board,

Future Farm Technologies Inc.

William Gildea, Chairman & CEO

About Future Farm

Future Farm Technologies Inc. is a Canadian company with projects throughout North America including California, Florida and Maryland. The Company’s business model includes developing and acquiring technologies that will position it as a leader in the evolution of Controlled Environment Agriculture (CEA) for the global production of various types of plants, with a focus on cannabis. Future Farm provides scalable, indoor CEA systems that utilize minimal land, water and energy regardless of climate, location or time of year and are customized to grow an abundance of crops close to consumers, therefore minimizing food miles and its impact to the environment. The Company holds an exclusive, worldwide license to use a patented vertical farming technology that, when compared to traditional plant production methods, generates yields up to 10 times greater per square foot of land.  The contained system provides many other benefits including 90% less water, fertilizer and land used, less travel costs, seed to sale security, scalability, consistency due to year-round production, cost control, product safety and purity by eliminating environmental variability.

The Company is also in the business of designing and distributing LED lighting solutions utilizing the COB and MCOB technology. The Company is focused on delivering cost efficient lighting to North America via advanced e-commerce sites the Company owns and operates. LEDCanada.com, which caters to B2B customers, is a supplier of the newest and highest demand LED solutions. The Company also owns and operates COBGrowlights.com, which caters to both large and small agriculture green houses and controlled cultivation centers.

Neither the Canadian Securities Exchange nor its Market Regulator (as that term is defined in the policies of the Canadian Securities Exchange) accepts responsibility for the adequacy or accuracy of this release. The Canadian Securities Exchange has not in any way passed upon the merits of the proposed transaction and has neither approved nor disapproved the contents of this press release. 

This news release may include forward-looking statements that are subject to risks and uncertainties. All statements within, other than statements of historical fact, are to be considered forward looking.  Although the Company believes the expectations expressed in such forward-looking statements are based on reasonable assumptions, such statements are not guarantees of future performance and actual results or developments may differ materially from those in forward-looking statements.  Factors that could cause actual results to differ materially from those in forward-looking statements include market prices, exploitation and exploration successes, continued availability of capital and financing, and general economic, market or business conditions.  There can be no assurances that such statements will prove accurate and, therefore, readers are advised to rely on their own evaluation of such uncertainties.  We do not assume any obligation to update any forward-looking statements except as required under the applicable laws.

Contact:
Future Farm Technologies Inc.
Bill Gildea
617 834 9467
bill@FutureFarmTech.com

Primary Logo

 

Source: GlobeNewswire (April 5, 2018 – 8:00 AM EDT)

The post Future Farm Provides Rhode Island Update and Announces Speaking Engagement at Thought Leadership in the Dominican Republic appeared first on CannabisFN.

Choom™: Four LP Applicants and a Killer Cannabis Brand

When the Choom Gang formed in Honolulu in the 1970’s, the group of friends were simply focused on living a relaxed lifestyle filled with island good times and choom, the local term for marijuana. Forty years later, the pipe dream of legal marijuana is coming to fruition and Choom™ Holdings Inc. (CSE: CHOO) (OTCQB: CHOOF) is building a recreational cannabis business around that relaxed lifestyle. With a plan to cultivate good times for its customers, Choom is quickly laying the groundwork for a retail cannabis operation to take advantage of Canada’s upcoming legalization. In a recreational market estimated to be in the neighborhood of $10.2 billion by 2023, the opportunity is substantial, according to recent industry reports.

Follow the link to get Choom’s corporate presentation and company updates.

Four Licensed Producer Applicants

Choom™ has acquired, or has agreements to acquire, four late-stage licensed producer applicants. The most recent agreement, to acquire Saskatchewan-based applicant High Way 10  and its parent company Flower Power Cannabis Pharms, represents a departure from the previous deals in a couple of important ways.

First, the other three producers are based in British Columbia, so the new deal represents geographical diversity that could become very important in the upcoming recreational market. While the federal government is creating the general legal framework for the industry, provinces are left to their own devices in setting up the details of the retail distribution system. In March, the Saskatchewan Liquor and Gaming Authority (SLGA) announced they would be issuing 51 retail permits (that number is limited for the first three years to ensure a controlled roll-out) to private companies, while the SLGA would regulate both the wholesale and retail market. Flower Power is currently involved in the application process with SLGA and hopes to secure retail licenses in several municipalities across Saskatchewan.

The second unique aspect of this deal lies in Flower Power’s approach to recreational branding and customer experience. The company’s mission is to ‘elevate the Cannabis Experience’ by welcoming consumers with their holistic approach and natural aesthetic. With its plan to roll out retail locations, the addition of Flower Power would expand Choom’s ability to scale their operations more quickly when legalization takes place.

Of course, the potential addition of a fourth licensed producer also means more production capacity for Choom. The company is committed to becoming a fully integrated cannabis enterprise, from cultivation through retail sale, and securing production capacity is crucial in carrying out this plan.

Choom™ retail store concept.

Implementing the Plan

Choom recently reached an agreement with ABcann Global that included a supply arrangement. ABcann is known for high quality cannabis product, and locking down a consistent and respected source allows Choom to jumpstart its retail implementation while it finalizes its own production processes. ABcann also contributed $4 million of a $7 million financing, money that will help Choom as it implements its plan for retail brand domination.

ABcann’s participation continues a trend in the industry as more established licensed producers, born and bred in the medical marijuana market, partner with and acquire more recreational-oriented assets. The partnership definitely validates Choom’s approach to branding and retail and should benefit both companies.

Follow the link to get Choom’s corporate presentation and company updates.

The Upshot

Choom Holdings is making great strides as it prepares to spread the good times and relaxed lifestyle of the Hawaiian beaches across Canada. This is definitely a company to watch as the Canadian cannabis industry transitions from a medical-only market to a significantly more lucrative adult-use market. Companies across the country are scrambling for position, and Choom appears poised to take advantage.

Disclaimer

The above article is sponsored content. Emerging Growth LLC, which owns CannabisFN.com and CFN Media, has been hired to create awareness. Please follow the link below to view our full disclosure outlining our compensation: http://www.cannabisfn.com/legal-disclaimer/

The post Choom™: Four LP Applicants and a Killer Cannabis Brand appeared first on CannabisFN.

Pivot Pharmaceuticals Provides Product Development Update

VANCOUVERApril 4, 2018 /PRNewswire/ – Pivot Pharmaceuticals Inc. (CSE: PVOT / OTCQB: PVOTF / FRA: NPAT) (“Pivot” or the “Company”) is pleased to provide a corporate update on the advancements of its industry leading bio-cannabis product pipeline. As previously announced, a 1% CBD Oral Micelle Solution developed in Germany is ready-to-market and development of two topical creams using the Company’s patented formulation and delivery systems is now complete.

In light of this development, the Company is anticipating that it will have several products available for sale in Canada on the date legalization officially begins. Pivot also projects to begin sales in California as of Q3 2018, including the launch of its proprietary line of “Ready-to-Infuse-Cannabis” (“RTIC”) natural health products. The sale of bulk powder, stick packs and capsules is expected to drive significant revenue.

The patents secured to date provide a significant opportunity for Pivot to create proprietary products that are unmatched in quality by current licensed producers and product distributors. The Company’s Intellectual Property portfolio covers several key patent areas which have previously demonstrated their ability to deliver pharmaceutical grade products in clinical trials. Pivot will now manufacture and commercialize its pipeline in anticipation of the legalization of cannabis in Canada as well as internationally, where regulations permit.

Pivot’s differentiated business model has entailed acquiring disruptive drug formulation and delivery technologies and then to develop dosable and reproducible bio-cannabis products for consumers. Pivot’s patent  protected products will enable the Company to secure sales free from competitors claiming similar activities.  According to the World Intellectual Property Organization (WIPO) pursuing a patent strategy allows Pivot to have:

  • Exclusive rights
  • Strong market position
  • Higher returns on investment
  • Opportunities to license or sell Inventions
  • Have a strong negotiation position with companies that may infringe

Dr. Joseph Borovsky, Pivot’s Vice President, Formulations, indicates that “our development team in Israel has now completed key development milestones with our nanoparticulate transdermal technology product as well as with our BiPhasix topical product.  These two lead product candidates will complete final testing and we will announce our scale-up and marketing strategy in the coming months.”

“Canadian Licensed Producers have invested extensively in dried flower and oil production capacity but have not focused on downstream sustainable quality products made from cannabis. Consumers deserve and will demand products that work, whereas regulatory authorities will require high quality, reproducible and safe products. Pivot has positioned itself to be the market leader of  bio-cannabis products,” said Dr. Patrick Frankham, Pivot’s CEO.

About Pivot Pharmaceuticals Inc.

Pivot Pharmaceuticals Inc. is a biopharmaceutical company engaged in the development and commercialization of therapeutic pharmaceuticals and nutraceuticals using innovative drug delivery platform technologies. Pivot’s wholly-owned medical cannabis products division, Pivot Green Stream Health Solutions Inc. (“PGS” or “Pivot Green Stream”), conducts research, development and commercialization of cannabinoid-based nutraceuticals and pharmaceuticals. PGS has acquired worldwide rights to “RTIC” Ready-To-Infuse Cannabis powder to oil technology, BiPhasix™ Transdermal Drug Delivery platform technology (topical), Solmic Solubilisation technology (oral) and Thrudermic Transdermal Nanotechnology (transdermal) for the delivery and commercialization of cannabinoid, cannabidiol (CBD), and tetrahydrocannabinol (THC)-based products.  PGS’ initial product development candidates will include topical treatments for women’s sexual dysfunction (PGS-N005), as well as psoriasis (PGS-N007), and an oral product (PGS-N001) for cancer supportive care. For more information please visit www.PivotPharma.com

Cautionary Statement

Except for historical information contained herein, the matters set forth above may be forward-looking statements that involve certain risks and uncertainties that could cause actual results to differ from those in the forward-looking statements. Words such as anticipate, project, believe, estimate, expect, intend, and similar expressions, as they relate to Pivot Pharmaceuticals Inc. or Pivot Green Stream Health Solutions Inc., or its management, identify forward-looking statements. Such forward-looking statements are based on the current beliefs of management, as well as assumptions made by and information currently available to management. Actual results could differ materially from those contemplated by the forward-looking statements as a result of certain factors, such as the failure to meet the conditions imposed by the CSE or other securities regulators, the level of business and consumer spending, the amount of sales of Pivot’s products, the competitive environment within the industry, the ability of Pivot to continue to expand its operations, the level of costs incurred in connection with Pivot’s expansion efforts, economic conditions in the industry, and the financial strength of Pivot’s customers and suppliers. Pivot does not undertake any obligation to update such forward-looking statements. Investors are also directed to consider all other risks and uncertainties.

SOURCE Pivot Pharmaceuticals Inc.

Source: PR Newswire (April 4, 2018 – 4:05 AM EDT)

The post Pivot Pharmaceuticals Provides Product Development Update appeared first on CannabisFN.

Delta 9 Exercises Option to Acquire Production Facility

WINNIPEGApril 4, 2018 /CNW/ – DELTA 9 CANNABIS INC. (TSXV: NINE) (“Delta 9” or the “Company”) is pleased to announce that it has exercised its option to purchase the land and 80,000 square foot building containing the Company’s current cannabis production facility (the “Property”) for a price of $6.25 million, subject to certain closing adjustments and conditions. Delta 9 previously announced on March 21, 2018 that it had entered into a five-year lease of the Property which contained an option to purchase and that Delta 9 anticipated quickly exercising such option.

Delta 9 Cannabis is a producer of medical cannabis based in Winnipeg, Manitoba. It was the fourth company in Canada licensed to grow marijuana for medical purposes, and trades on the TSX-V under the symbol NINE. (CNW Group/Delta 9 Cannabis Inc.)

Delta 9 has entered into a formal option agreement (the “Option Agreement”) with 6599362 Canada Ltd. (the “Vendor”) which sets forth the terms of the acquisition of the Property. The Option Agreement also provides that on closing of the acquisition of the Property, Delta 9 will purchase certain cannabis production equipment (the “Equipment”) currently leased from the Vendor pursuant to certain lease agreements for a price of $952,000, plus applicable taxes.

The Vendor is a non-arm’s length party of Delta 9 due to the fact that a director of Delta 9, Joanne Duhoux-Defehr, is also a director of the Vendor and is the owner of 20 per cent of the issued and outstanding shares of the Vendor. Accordingly, the acquisition of the Property and the Equipment are considered to be a non-arm’s length party transaction and will be subject to the approval of the TSX Venture Exchange (the “Exchange”). The Exchange will require Delta 9 to provide evidence of the value of the Property and Equipment to the Exchange to support the purchase price being paid by Delta 9 as well as certain other information. Closing is also subject to the completion of satisfactory due diligence by Delta 9 as well as certain other closing conditions.

As previously announced, the Property is located in a heavy industrial area in Winnipeg, Manitoba. The production facility of Delta 9 has been located at the Property since July, 2013. Delta 9 has made significant improvements to the Property to enable it to be used as a cannabis cultivation facility. Management of Delta 9 believes that the acquisition of the Property will be positive for Delta 9 as it will allow Delta 9 to obtain complete ownership and control over its current cannabis production facility.

“Delta 9 has designed a highly efficient growing method through the development of our proprietary Grow Pod technology, and by purchasing the property we will be able to custom design and build structures that are ideally suited to house our cannabis Grow Pods,” says CEO John Arbuthnot.

“This land purchase would not only secure our current expansion to 17,500 kilograms of cannabis annually, but would also secure our long term expansion on the same property.”

About Delta 9 Cannabis Inc.
Delta 9’s wholly-owned subsidiary, Delta 9 Bio-Tech Inc., is a licensed producer of medical marijuana pursuant to the ACMPR and operates an 80,000 square foot production facility in Winnipeg, Manitoba, Canada. Delta 9 was the fourth company in Canada licensed to produce legal cannabis. Delta 9’s shares trade on the TSX Venture Exchange under the symbol “NINE”.

Neither the TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in the policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release.

Disclaimer for Forward-Looking Information

Certain statements in this release are forward-looking statements, which reflect the expectations of management regarding the Company’s future business plans and other matters. Forward-looking statements consist of statements that are not purely historical, including any statements regarding beliefs, plans, expectations or intentions regarding the future. Forward looking statements in this news release include statements relating to the closing of the acquisition of the Property by Delta 9 and Exchange approval for such acquisition. Such statements are subject to risks and uncertainties that may cause actual results, performance or developments to differ materially from those contained in the statements, including that Delta 9’s currently contemplated expansion and development plans may cease or otherwise change, Delta 9’s production of cannabis may be lower than expected, Delta 9 may not obtain the required approvals from Health Canada, demand for Delta 9’s products may be lower than anticipated, Delta 9’s cost to produce its grow pods may be higher than expected and all other risk factors set forth in the filing statement of Delta 9 dated October 25, 2017 which has been filed on SEDAR. No assurance can be given that any of the events anticipated by the forward-looking statements will occur or, if they do occur, what benefits the Company will obtain from them. Readers are urged to consider these factors carefully in evaluating the forward-looking statements contained in this news release and are cautioned not to place undue reliance on such forward-looking statements, which are qualified in their entirety by these cautionary statements. These forward-looking statements are made as of the date hereof and the Company disclaims any intent or obligation to update publicly any forward-looking statements, whether as a result of new information, future events or results or otherwise, except as required by applicable securities laws.

SOURCE Delta 9 Cannabis Inc.

View original content with multimedia: http://www.newswire.ca/en/releases/archive/April2018/04/c2010.html

Gary Symons, Director of Communications, communications@delta9.ca, 250.300.9352Copyright CNW Group 2018

Source: Canada Newswire (April 4, 2018 – 5:30 AM EDT)

The post Delta 9 Exercises Option to Acquire Production Facility appeared first on CannabisFN.

Friday Night Reports Strong Revenue Growth in Path to Profitability

The cannabis industry is expected to surpass $50 billion by 2026, according to Cowen & Co., driven by the legalization of adult-use and medical cannabis in a growing number of states. In addition to California, Nevada has become one of the most promising states that has legalized adult-use cannabis given its enormous tourism industry. Investors looking for exposure to the market should look no further than Friday Night Inc. (CSE: TGIF) (OTCQB: TGIFF).

Friday Night is a majority-owner of the first licensed cultivation facility in the Las Vegas area, Alternative Medicine Association (AMA), as well as a developer of hemp and cannabidiol (CBD) infused product maker, Infused Mfg. The diversification between cannabis cultivation and hemp-based CBD products helps expand revenue streams and reduce risk, while its presence in Nevada targets one of the country’s largest recreational markets.

Strong Revenue Growth

Friday Night has seen significant revenue growth from its AMA and Infused Mfg businesses, which sets it apart from many other development-stage cultivators.

During the fiscal second quarter, the company announced a 20.2 percent sequential increase in revenue from $2,464,487 to $2,962,699 with six-month sales reaching $5.4 million. It’s worth noting that these revenue increases came despite November and December being very slow months for Las Vegas tourism. Management anticipates that revenue will move higher in future periods as tourism ticks up and the market matures.

Infused Mfg. experienced the fastest growth rate at 45 percent as it expanded both its product lines and target markets, while Alternative Medicine Association’s growth rates were in-line with management expectations at ten percent over the quarter. Management anticipates that AMA’s revenue is poised to grow significantly after the new cultivation facility comes online given the Nevada market’s chronically short cannabis supply.

On the bottom line, gross profits reached $1,579,127, representing attractive gross margins of about 53.3 percent, while the company’s balance sheet remains robust with $15,753,139 in cash and cash equivalents. These cash reserves provide ample buying power to complete future acquisitions and build out its new cultivation facility in Nevada, while strong profit margins pave the way towards profitability over the coming years.

Setting the Stage

Friday Night’s priority is the construction of its new 67,000 sq. ft. building to achieve higher production. After acquiring the land and securing zoning approval, the company is awaiting final plan approval from the county. Management had originally planned to have the new building operational by now, but regulatory delays and changes to the plans (from a one-story 35,000 sq. ft. facility to a two-story 67,000 sq. ft. facility) have delayed construction.

The company has also made progress in building new revenue streams:

  • On November 3, 2017, the company reached an exclusive agreement with MariMed Advisors to produce THC products, including their unique sublingual “Melts” product line, a THC and CBD “Mints” line, “Kalm Corn” products, and the “Betty Eddies” and “Berry Bombs” line of products. Under the agreement, AMA produces these products and distributes them to all dispensaries in Nevada.
  • On December 6, 2017, the company announced that AMA signed a production contract to produce high-grade concentrates for a major dispensary chain in Nevada.

In the fiscal third quarter beginning January 1, 2018, the company acquired a new wholly-owned subsidiary, Spire Secure Logistics Inc., which is a Canadian firm specializing in security, intelligence, and compliance with international clients. The acquisition enables the company to generate significant cash flow potential that is not constrained by local government regulations, but still benefits from the rapidly growing cannabis sector.

Management also continues to look at various acquisition targets to augment its current operations, both within and outside of Nevada. It has entered into numerous LOIs that did not close as management determined these acquisitions either did not meet its stringent specifications or the asking price was not justifiable. This includes the LOI to acquire Body & Mind Inc. in an all-stock transaction that was terminated on February 21, 2018.

Looking Ahead

Friday Night Inc. (CSE: TGIF) (OTCQB: TGIFF) represents a compelling investment opportunity in the legal cannabis space. In addition to its existing revenue growth, the company’s Nevada facility is nearing final approval and could produce significant shareholder value over the coming years once complete. Investors may want to take a closer look at the stock given these significant catalysts moving forward.

For more information, visit the company’s website or download their investor presentation.

Disclaimer

The above article is sponsored content. Emerging Growth LLC, which owns CannabisFN.com and CFN Media, has been hired to create awareness. Please follow the link below to view our full disclosure outlining our compensation: http://www.cannabisfn.com/legal-disclaimer/

The post Friday Night Reports Strong Revenue Growth in Path to Profitability appeared first on CannabisFN.

Micron Waste Technologies (MWM) at the Forefront of Cannabis Disposal Issues

As the Canadian government inches closer to full legalization of adult-use cannabis, the details involved in the regulation of all aspects of the industry are raising additional questions that had not previously been widely considered. One issue being studied by the Standing Senate Committee on Agriculture and Forestry (AGFO) is the possible effects of cannabinoid residues on the environment, and the proper methods for cannabis waste disposal. With the volume of (legal) cannabis waste expected to increase dramatically over the next few years, the government is trying to get ahead of the challenge of how to properly dispose of tons of stalks and trimmings produced by the legal industry.

On March 27, 2018, AGFO heard testimony presented by Micron Waste Technologies (CSE: MWM) (OTC: MICWF) regarding the company’s organic waste treatment solution. Already proven in supermarket applications for the treatment of food waste, the company’s technology could go a long way in helping Canada minimize the environmental impacts of the burgeoning legal cannabis industry.

Micron and Aurora Cannabis Team Up

Micron Waste had developed and launched its waste disposal system for food waste, but was eyeing the cannabis industry as a potentially lucrative vertical. In January, 2018, the company announced a groundbreaking collaboration with Aurora Cannabis Inc., one of Canada’s leading licensed producers.

Aurora invested about $1.5 million in Micron as part of a larger private placement. The companies agreed to install the initial waste digester unit at one of Aurora’s production facilities, and the installation is on track for June, 2018. The companies agreed to work together to optimize the technology onsite before installing more units at Aurora’s other facilities as well as pitching the solution to other producers.

Cam Battley, Aurora’s Chief Corporate Officer and Micron Director, joined Micron President Alfred Wong in presenting testimony to AGFO on how the organic waste digester can solve waste problems for the cannabis industry. With many cannabis companies pitching themselves as ‘green’ and looking to limit environmental impacts by reducing energy use and eliminating pesticides, Micron’s organic on-site technology fits in nicely with the direction the industry is taking.

“Micron’s solution is on track to be installed at Aurora’s facility by June of this year,” Mr. Wong testified. “This on-site process will minimise the cost of shipping cannabis waste to landfill or composting facilities and will help reduce greenhouse gas emissions and carbon footprint. Our clean agricultural technology will provide licensed producers with an environmentally-sound, cost-effective solution for cannabis waste treatment and is anticipated to be able to meet the scale of Canada’s growing cannabis industry.”

The Advantages of Micron’s Solution

Cannabis producers are mandated to track every ounce of product, including waste. According to a recent article on the industry in Washington state, very few producers are composting their waste, either by employing industrial composting services or by composting on site. Almost all of the waste is going to public landfills, an inefficient and expensive process that also happens to increase the carbon footprint of the producers’ operations. Even if industrial composters are utilized, the waste needs to be trucked from the production site and the service paid for by the producer. If a producer chooses to compost on its own, the operation takes up a lot of space that might be more profitably utilized in cannabis production. In short, no existing solution checks all of the boxes: environmentally friendly, convenient, inexpensive, elegant.

Micron’s technology checks all of these boxes. Installed onsite, the digester removes the need to transport the waste off site, thereby reducing the impacts of trucking and landfill use. Due to its highly efficient design, the digester takes up much less space and requires much less oversight than traditional composting methods. Waste is broken down within a couple of days, much more quickly than with traditional composting operations. Cannabis waste is turned into sewage friendly product, and water used in the process could be recirculated and repurposed for other onsite uses like watering the plants and cleaning more waste.

Where Micron is Headed

Cannabis waste disposal is a problem that was perhaps not fully considered in the implementation of legal cannabis regulations, both in Canada and the United States. Canada is considering solutions ahead of recreational legalization, and Micron (with an assist from Aurora) is at the forefront of the search for viable solutions. Keep an eye on the Canadian government’s proceedings, as well as on Micron Waste Technologies’ developments as the initial units are installed, the technology refined, and the products commercialized. The company appears to have a solution to a problem that is much larger than people anticipated.

The post Micron Waste Technologies (MWM) at the Forefront of Cannabis Disposal Issues appeared first on CannabisFN.